{"gene":"PRKCI","run_date":"2026-04-28T19:45:45","timeline":{"discoveries":[{"year":1993,"finding":"PKC iota (PRKCI) was molecularly cloned and characterized as a novel atypical PKC isoform. It encodes a 587-amino acid serine-threonine kinase with greatest homology to PKC zeta (72% overall, 84% in catalytic domain), contains a conserved pseudosubstrate sequence, lacks a Ca2+-binding region, and has only one cysteine-rich zinc finger-like domain. Stable expression in CHO-K1 cells showed a 65 kDa protein with increased kinase activity toward myelin basic protein.","method":"cDNA cloning, Northern blot, Western blot, in vitro kinase assay","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1 — original cloning with biochemical validation of kinase activity","pmids":["8226978"],"is_preprint":false},{"year":1996,"finding":"The product of the pro-apoptotic par-4 gene specifically interacts with the regulatory domains of atypical PKC isoforms (zeta PKC and lambda/iota PKC), dramatically inhibiting their enzymatic activity. Cotransfection of wild-type (but not kinase-inactive) atypical PKCs abrogated par-4-induced apoptotic morphological changes in NIH-3T3 cells, establishing that atypical PKC activity promotes cell survival downstream of par-4.","method":"Co-immunoprecipitation, in vitro kinase assay, dominant-negative mutagenesis, cell transfection with apoptosis readout","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1–2 — reciprocal interaction, kinase-dead mutant rescue, multiple orthogonal methods","pmids":["8797824"],"is_preprint":false},{"year":1999,"finding":"Atypical PKC isoforms (lambda/iota PKC and zeta PKC) activate NF-κB through direct binding and phosphorylation of IKKβ (at Ser177 and Ser181), but not IKKα. Dominant-negative lambda/iota PKC impairs RIP-stimulated NF-κB activation. Recombinant active atypical PKC directly phosphorylates IKKβ in vitro, placing atypical PKCs upstream of IKKβ in the TNFα-NF-κB pathway.","method":"Co-immunoprecipitation, in vitro kinase assay, dominant-negative transfection, site-directed mutagenesis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstituted phosphorylation, mutagenesis of substrate sites, epistasis","pmids":["10022904"],"is_preprint":false},{"year":1999,"finding":"The aPKC-binding protein p62 selectively interacts with RIP (but not TRAF2), bridging the atypical PKCs to RIP in the TNFα signaling pathway. This establishes a signaling cascade: TNF-R1→TRADD/RIP/p62/aPKCs/IKKβ for NF-κB activation. Dominant-negative lambda/iota PKC impairs RIP-stimulated NF-κB activation, and antisense p62 severely abrogates NF-κB activation.","method":"Co-immunoprecipitation, in vitro binding assay, dominant-negative transfection, antisense knockdown, NF-κB reporter assay","journal":"The EMBO journal","confidence":"High","confidence_rationale":"Tier 1–2 — multiple orthogonal methods, defined pathway position by epistasis","pmids":["10356400"],"is_preprint":false},{"year":2000,"finding":"Par6 forms a complex with Cdc42-GTP, a human homologue of PAR-3, and the regulatory domains of atypical PKC (including PKCι). This Par6-Par3-aPKC-Cdc42 complex is required for formation of normal tight junctions at epithelial cell-cell contacts, linking Cdc42 polarity signaling to atypical PKC via Par6 as a key adaptor.","method":"Yeast two-hybrid, Co-immunoprecipitation, dominant-negative expression, tight junction permeability assay","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 — reciprocal Co-IP, functional tight junction assay, replicated across labs","pmids":["10934474"],"is_preprint":false},{"year":2001,"finding":"Atypical PKC (aPKC, including the iota isoform) is a component of the evolutionarily conserved PAR protein complex (aPKC-ASIP/PAR-3-PAR-6 ternary complex) that localizes to the apical junctional region of MDCK epithelial cells. Overexpression of dominant-negative aPKC causes mislocalization of PAR-3, severely disrupts tight junction biogenesis, increases paracellular ion diffusion, and impairs epithelial apico-basal polarity.","method":"Dominant-negative mutagenesis, immunocytochemistry, paracellular diffusion assay, Co-immunoprecipitation","journal":"The Journal of cell biology","confidence":"High","confidence_rationale":"Tier 1–2 — dominant-negative with multiple orthogonal functional readouts, replicated","pmids":["11257119"],"is_preprint":false},{"year":2003,"finding":"The PB1 (Phox and Bem1p) domain mediates interactions between atypical PKCs (lambda/iota and zeta PKC) and scaffold proteins p62 and Par6. Mutation analyses identified critical basic charge cluster residues in aPKC PB1 domains that interact with an acidic loop/helix in p62, establishing molecular basis for aPKC coupling to NF-κB and cell polarity signaling pathways.","method":"Mutation analysis, molecular modeling, Co-immunoprecipitation, yeast two-hybrid","journal":"The Journal of biological chemistry","confidence":"High","confidence_rationale":"Tier 1–2 — mutagenesis defining interaction surfaces, multiple interacting pairs tested","pmids":["12813044"],"is_preprint":false},{"year":2005,"finding":"Zebrafish heart and soul (Has)/PRKCi is required tissue-autonomously within the myocardium for normal heart morphogenesis, and this function depends on its catalytic activity. PRKCi and Nok/Mpp5 (Pals1) are required early for polarized epithelial organization and coherence of myocardial cells during heart cone formation, placing PRKCi as essential for apicobasal polarity in cardiac tissue.","method":"Genetic rescue (catalytic-dead mutant), tissue-specific mosaic analysis, live imaging, zebrafish mutant phenotype","journal":"Development (Cambridge, England)","confidence":"High","confidence_rationale":"Tier 2 — catalytic-dead mutant shows activity dependence, tissue-autonomous rescue","pmids":["16319113"],"is_preprint":false},{"year":2009,"finding":"In zebrafish spinal cord, loss of PrkCi function causes neural precursor divisions to become oblique during late embryogenesis, resulting in excess oligodendrocyte production and loss of dividing progenitor cells. PrkCi is required for planar cell division orientation and asymmetric self-renewing division of spinal cord precursors, acting through apicobasal polarity maintenance.","method":"Time-lapse imaging, zebrafish loss-of-function, cell fate analysis (oligodendrocyte vs. progenitor counting)","journal":"Developmental dynamics","confidence":"Medium","confidence_rationale":"Tier 2 — live imaging with defined phenotypic readout in single model organism","pmids":["19449304"],"is_preprint":false},{"year":2012,"finding":"The analog-sensitive kinase method was adapted for in vivo use in zebrafish embryos to identify PKCι substrates. Analog-sensitive Prkci uniquely thiophosphorylates substrates using bulky ATPγS analogs, enabling enrichment and identification of kinase substrates by immunoaffinity purification of thiophosphopeptides in the developing embryo.","method":"Analog-sensitive kinase/chemical genetics, mass spectrometry, thiophosphopeptide immunoaffinity purification in zebrafish","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 1 — chemical-genetic substrate identification method; foundational methodology paper without full substrate list","pmids":["22768194"],"is_preprint":false},{"year":2014,"finding":"PKCι phosphorylates SOX2 and recruits it to the promoter of Hedgehog acyltransferase (HHAT), the rate-limiting enzyme in Hh ligand production. PKCι-mediated SOX2 phosphorylation is required for HHAT promoter occupancy and HHAT expression, establishing a PKCι-SOX2-HHAT signaling axis that drives a stem-like phenotype in lung squamous cell carcinoma. PRKCI and SOX2 are coamplified on chromosome 3q26.","method":"In vitro kinase assay (PKCι phosphorylates SOX2), chromatin immunoprecipitation (promoter occupancy), siRNA knockdown, reporter assay, mouse tumor model","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 1–2 — direct phosphorylation demonstrated in vitro, ChIP for promoter occupancy, multiple functional readouts","pmids":["24525231"],"is_preprint":false},{"year":2016,"finding":"PRKCI overexpression impairs functional autophagy in U2OS cells, as evidenced by decreased LC3B-II levels and reduced degradation of autophagic substrates. Conversely, PRKCI knockdown induces autophagy. Two novel dominant-negative PRKCI mutants (L485M and P560R) also induce autophagy. Mechanistically, PRKCI knockdown-mediated autophagy is associated with inactivation of the PIK3CA/AKT-MTOR signaling pathway.","method":"siRNA knockdown, overexpression, site-directed mutagenesis, LC3B-II western blot, autophagic flux assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — KD/KO with defined molecular readout and pathway identification, single lab","pmids":["26792725"],"is_preprint":false},{"year":2016,"finding":"Prkci is required for non-autonomous polarity cue production during cavitation in embryoid bodies. Prkci-null cells fail to properly segregate apical-basal proteins and cannot form a coordinated ectodermal epithelium. When mixed with wildtype cells, cavitation is rescued, indicating Prkci is required to produce (not respond to) non-autonomous polarity cues. Neither BMP4 nor EZRIN overexpression fully rescues the polarized epithelium.","method":"Knockout ES cells, chimeric embryoid bodies, live imaging, immunofluorescence, BMP4/EZRIN rescue experiments","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis via chimeric rescue, defined non-autonomous role","pmids":["27312576"],"is_preprint":false},{"year":2017,"finding":"PRKCI promotes immune suppression in ovarian cancer by upregulating TNFα to generate a myeloid-derived suppressor cell-enriched, cytotoxic T-cell-depleted tumor microenvironment. YAP1 was identified as a downstream effector of PRKCI in ovarian tumor progression, establishing a PRKCI-YAP1 signaling axis in immune evasion.","method":"Transgenic mouse model, cytokine measurement, immune cell profiling (MDSC/T-cell quantification), siRNA knockdown, system-level analysis","journal":"Genes & development","confidence":"Medium","confidence_rationale":"Tier 2 — transgenic model with functional immune phenotype, pathway placement via YAP1","pmids":["28698296"],"is_preprint":false},{"year":2017,"finding":"PRKCI is a direct target of miR-29c in dorsal root ganglia neurons. High glucose upregulates miR-29c which reduces PRKCI protein, impairing axonal growth. Knockdown of endogenous miR-29c restores PRKCI protein and axonal growth under high glucose. Knockdown of PRKCI itself under normal glucose inhibits axonal growth, establishing PRKCI as a positive regulator of axonal growth in DRG neurons.","method":"Dual-luciferase 3'UTR reporter assay, siRNA knockdown, Western blot, axonal growth measurement in DRG neurons","journal":"Molecular neurobiology","confidence":"Medium","confidence_rationale":"Tier 2–3 — direct 3'UTR validation, siRNA rescue, defined cellular phenotype","pmids":["28070856"],"is_preprint":false},{"year":2020,"finding":"Chromosome 3q26 copy number gains occur early in LSCC tumorigenesis and drive coordinate overexpression of PRKCI, SOX2, and ECT2. PRKCI and SOX2 collaborate to activate a transcriptional program enforcing LSCC lineage, while PRKCI and ECT2 collaborate to promote oncogenic growth. Overexpression of all three oncogenes with Trp53 loss transforms mouse lung basal stem cells into histological LSCC.","method":"Mouse transformation model (basal stem cell), genomic analysis, gene expression profiling, siRNA knockdown, mouse tumor formation","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 2 — in vivo transformation model, multiple oncogene combinations tested, defined transcriptional program","pmids":["31968252"],"is_preprint":false},{"year":2020,"finding":"PKCι interacts with RIPK2 kinase in pancreatic cancer cells, as demonstrated by co-immunoprecipitation and immunofluorescence. The PRKCI-RIPK2 complex enhances phosphorylation of downstream NF-κB, JNK, and ERK signaling. RIPK2 knockout inhibits subcutaneous tumor growth and liver metastasis of pancreatic cancer and suppresses autophagosome formation while increasing ROS and apoptosis.","method":"Co-immunoprecipitation, immunofluorescence, RIPK2 knockout (in vitro and xenograft), phosphorylation analysis by Western blot","journal":"Molecular medicine (Cambridge, Mass.)","confidence":"Medium","confidence_rationale":"Tier 2–3 — Co-IP interaction, in vivo xenograft, multiple signaling readouts; single lab","pmids":["37016317"],"is_preprint":false},{"year":2022,"finding":"Pancreas-specific Prkci knockout increases acinar cell DNA damage, apoptosis, immune cell infiltration, and causes P62 aggregation with loss of autophagic vesicles, establishing PKCι as required for pancreatic acinar cell autophagy. Loss of pancreatic Prkci promoted Kras-mediated pancreatic intraepithelial neoplasia formation but blocked progression to adenocarcinoma, consistent with an autophagy-dependent mechanism.","method":"Conditional pancreas-specific Prkci knockout mouse, histology, immunostaining for P62/autophagy markers, caerulein pancreatitis model, KrasG12D cancer progression model","journal":"Cancers","confidence":"High","confidence_rationale":"Tier 2 — conditional KO with multiple tissue-specific readouts in vivo, epistasis with Kras","pmids":["35159064"],"is_preprint":false},{"year":2022,"finding":"A point mutation in Prkci (identified in Tvrm323 mice) acts as a genetic modifier of Crb1-associated retinal dysplasia. Epistasis analysis showed the increased dysplastic phenotype required homozygosity of the Crb1rd8 allele, establishing Prkci as a modifier gene that shapes Crb1-associated retinal disease, likely through its role in apicobasal polarity.","method":"Chemical mutagenesis screen, genetic mapping, exome sequencing, epistasis analysis, immunohistology, electroretinography","journal":"PLoS genetics","confidence":"Medium","confidence_rationale":"Tier 2 — genetic epistasis in mouse model, but mechanism not fully defined at molecular level","pmids":["35675330"],"is_preprint":false},{"year":2022,"finding":"PRKCI mediates radiosensitivity in cervical cancer through the Hedgehog/GLI1 pathway. PRKCI functions downstream of the Hh/GLI1 pathway, phosphorylating and activating transcription factor GLI1. PRKCI knockdown alters GLI1 relocalization and phosphorylation, increasing radiosensitivity, and the PKCι inhibitor auranofin acts as a radiosensitizer in vitro and in vivo.","method":"Knockdown/overexpression, colony formation assay, flow cytometry (apoptosis/cell cycle), Western blot, immunofluorescence, xenograft","journal":"Frontiers in oncology","confidence":"Medium","confidence_rationale":"Tier 2–3 — KD with multiple readouts, pathway placement, but GLI1 phosphorylation not directly demonstrated in vitro","pmids":["35785194"],"is_preprint":false},{"year":2024,"finding":"PRKCI interacts with SQSTM1/p62 (by co-immunoprecipitation) in osteosarcoma cells. Knockdown of PRKCI inhibits proliferation, migration, invasion, and arrests cell cycle at G2/M, operating through inactivation of the Akt/mTOR signaling pathway.","method":"Co-immunoprecipitation, siRNA knockdown, CCK-8, transwell, flow cytometry, Western blot for Akt/mTOR pathway","journal":"Frontiers in oncology","confidence":"Low","confidence_rationale":"Tier 3 — single Co-IP, single lab, KD phenotype without mechanistic reconstitution","pmids":["39015499"],"is_preprint":false},{"year":2025,"finding":"Rare loss-of-function variants in PRKCI cause Van der Woude syndrome (lower lip pits and orofacial clefts). Functional validation in zebrafish confirmed three alleles (p.Arg130His, p.Asn383Ser, p.Leu385Phe) as loss-of-function. Phosphomimetic IRF6 rescues aPKC inhibition effects, placing PRKCI upstream of IRF6 in the periderm transcriptional regulatory network governing palatal fusion.","method":"Zebrafish functional assay (enveloping layer/periderm), genetic analysis of de novo variants, phosphomimetic IRF6 rescue experiment","journal":"American journal of human genetics","confidence":"High","confidence_rationale":"Tier 2 — multiple alleles functionally validated in zebrafish, epistasis with IRF6 established by rescue","pmids":["40902599"],"is_preprint":false},{"year":2025,"finding":"The PAR6B-PRKCI-PAR3 polarity complex regulates the cell cycle of type II alveolar epithelial cells (AEC2s). Reduced PAR3-PARD6B-PRKCI complex levels arrest AEC2 cell cycle in the G0-G1 phase, impairing self-proliferation and contributing to abnormal alveolar repair in the emphysema subtype of COPD.","method":"Co-immunoprecipitation, mass spectrometry, 3D spheroid formation, viral transfection, cell cycle analysis","journal":"Stem cell research & therapy","confidence":"Medium","confidence_rationale":"Tier 2 — Co-IP/MS identifies complex, functional assay links complex to cell cycle; single lab","pmids":["40001200"],"is_preprint":false},{"year":2025,"finding":"Prkci phosphorylates and stabilizes TGFβ receptor 1 (Tgfbr1), preventing its proteasomal degradation and amplifying downstream TGF-β signaling cascades in colorectal cancer. This stabilization promotes epithelial-to-mesenchymal transition, migration, and invasion. In vivo, Prkci knockout significantly reduced liver and lung metastases in mouse models.","method":"Co-immunoprecipitation, in vitro kinase assay (phosphorylation of Tgfbr1), proteasome inhibitor rescue, EMT marker analysis, Prkci knockout mouse xenograft","journal":"Cell communication and signaling","confidence":"Medium","confidence_rationale":"Tier 2 — direct substrate phosphorylation shown, stabilization mechanism validated, in vivo confirmation; single lab","pmids":["40382656"],"is_preprint":false},{"year":2025,"finding":"Prkci phosphorylates c-Myc at serine 21, inhibiting its ubiquitin-mediated proteasomal degradation and stabilizing c-Myc protein. The pro-proliferative effect of Prkci in colorectal cancer is dependent on c-Myc S21 phosphorylation. Prkci deletion in mouse models significantly delayed tumor growth and improved survival.","method":"Co-immunoprecipitation, in vitro kinase assay, site-directed mutagenesis (S21 phosphosite), ubiquitination assay, Prkci knockout mouse tumor model","journal":"NPJ precision oncology","confidence":"Medium","confidence_rationale":"Tier 1–2 — direct phosphorylation at defined site, mutagenesis confirms site, in vivo validation; single lab","pmids":["41188443"],"is_preprint":false},{"year":2025,"finding":"Prkci promotes tumor angiogenesis in colorectal cancer by phosphorylating Jak2 at serine 633, leading to downstream Stat3 activation and increased Vegfa expression. In vitro, Prkci overexpression enhanced endothelial cell proliferation, migration, and tube formation. Prkci knockout in CRC cells significantly reduced tumor growth and angiogenesis in vivo.","method":"In vitro kinase assay (Jak2 S633 phosphorylation), endothelial cell functional assays (proliferation, migration, tube formation), Prkci knockout xenograft","journal":"Neoplasia (New York, N.Y.)","confidence":"Medium","confidence_rationale":"Tier 1–2 — direct phosphorylation at defined site, multiple in vitro/in vivo functional readouts; single lab","pmids":["40840329"],"is_preprint":false},{"year":2024,"finding":"Neural progenitor-specific ablation of both Prkci and Prkcz aPKC paralogs in mouse brain reveals a critical developmental window wherein aPKC kinase function is indispensable for neurodevelopment. A kinase-inactive PRKCI knock-in confirms that catalytic activity is required during this window. Outside this period, loss of both aPKCs causes unexpectedly mild effects.","method":"Conditional knockout mice (neural stem cells, neurons, astrocytes, NG2+ cells), kinase-inactive knock-in, gross brain morphology and viability assessment","journal":"bioRxiv","confidence":"Medium","confidence_rationale":"Tier 2 — kinase-dead knock-in confirms catalytic requirement; preprint, single lab","pmids":[],"is_preprint":true}],"current_model":"PKCι (PRKCI) is an atypical serine-threonine kinase that functions as a catalytic component of the evolutionarily conserved PAR3-PAR6-aPKC polarity complex (linked to Cdc42 via Par6) to establish and maintain apicobasal epithelial polarity, tight junctions, and oriented cell division; it activates NF-κB by phosphorylating IKKβ (facilitated by the p62-RIP scaffold via PB1 domain interactions); in cancer contexts it phosphorylates SOX2 to drive Hedgehog/HHAT expression, phosphorylates GLI1, Tgfbr1, Jak2 (S633), and c-Myc (S21) to promote oncogenic signaling, metastasis, and angiogenesis; and it sustains autophagy flux through the PIK3CA/AKT-MTOR pathway in pancreatic acinar cells, while loss-of-function variants cause Van der Woude syndrome by disrupting periderm differentiation upstream of IRF6."},"narrative":{"teleology":[{"year":1993,"claim":"Molecular cloning of PRKCI established it as a novel atypical PKC isoform most closely related to PKCζ, possessing serine/threonine kinase activity but lacking the Ca²⁺-binding and dual cysteine-rich motifs of conventional PKCs, thereby defining a distinct regulatory input logic for this branch of the PKC family.","evidence":"cDNA cloning, Northern/Western blot, in vitro kinase assay in CHO-K1 cells","pmids":["8226978"],"confidence":"High","gaps":["No endogenous substrates identified","Tissue-specific expression pattern not fully mapped","Activation mechanism in cells unknown"]},{"year":1996,"claim":"Identification of Par-4 as a specific inhibitor of atypical PKCs (including PKCι) that promotes apoptosis established that PKCι kinase activity functions as a pro-survival signal, answering whether atypical PKCs have roles beyond conventional PKC-regulated pathways.","evidence":"Co-immunoprecipitation, in vitro kinase assay, kinase-dead mutant rescue in NIH-3T3 cells","pmids":["8797824"],"confidence":"High","gaps":["Mechanism by which Par-4 inhibits aPKC catalytic activity not resolved","Downstream survival substrates not identified"]},{"year":1999,"claim":"Demonstration that PKCι directly phosphorylates IKKβ (Ser177/Ser181) and that the scaffold protein p62 bridges PKCι to RIP in the TNFα pathway placed PKCι at a defined position in NF-κB activation, resolving how atypical PKCs connect receptor signaling to IKK.","evidence":"In vitro kinase assay, site-directed mutagenesis, dominant-negative transfection, antisense p62, NF-κB reporter","pmids":["10022904","10356400"],"confidence":"High","gaps":["Relative contribution of PKCι vs. PKCζ to NF-κB in vivo not resolved","Structural basis of p62–aPKC interaction unknown at this time"]},{"year":2000,"claim":"Discovery that PKCι forms a ternary complex with Par6, Par3, and Cdc42-GTP at tight junctions revealed the conserved polarity machinery through which PKCι controls epithelial apicobasal polarity, answering how a kinase connects Rho-family GTPase signaling to junction formation.","evidence":"Yeast two-hybrid, reciprocal Co-IP, dominant-negative expression, tight junction permeability assay in epithelial cells","pmids":["10934474","11257119"],"confidence":"High","gaps":["Direct phosphorylation substrates within the polarity complex not identified","How kinase activity remodels the complex unclear"]},{"year":2003,"claim":"Mapping the PB1 domain as the module mediating PKCι interactions with both p62 and Par6 unified the NF-κB and polarity functions under a single structural interface, explaining how one kinase is routed to distinct pathways through competitive PB1-mediated scaffolding.","evidence":"Mutagenesis of basic/acidic charge residues, Co-IP, yeast two-hybrid","pmids":["12813044"],"confidence":"High","gaps":["Whether p62 and Par6 binding is mutually exclusive in vivo not tested","No crystal structure of the PB1 heterodimer at this time"]},{"year":2005,"claim":"Genetic studies in zebrafish demonstrated that PKCι catalytic activity is required tissue-autonomously for cardiac and neural progenitor polarity and morphogenesis, extending the polarity function from cultured epithelial cells to in vivo organogenesis.","evidence":"Zebrafish heart-and-soul mutant rescue with catalytic-dead mutant, mosaic analysis, live imaging; spinal cord progenitor division analysis","pmids":["16319113","19449304"],"confidence":"High","gaps":["In vivo substrates mediating cardiac morphogenesis unknown","Whether PKCζ compensates partially in zebrafish not addressed"]},{"year":2014,"claim":"Identification of SOX2 as a direct PKCι substrate whose phosphorylation drives HHAT transcription and Hedgehog ligand production revealed the first oncogenic phosphorylation circuit for PKCι, explaining how 3q26 amplification promotes lung squamous cell carcinoma stemness.","evidence":"In vitro kinase assay, ChIP, siRNA, reporter assay, mouse tumor model","pmids":["24525231"],"confidence":"High","gaps":["SOX2 phosphosite(s) not fully mapped","Whether this axis operates in non-lung cancers unclear"]},{"year":2016,"claim":"PRKCI was shown to suppress autophagy via PIK3CA/AKT–mTOR activation, while dominant-negative PRKCI mutants induced autophagy, establishing a kinase activity–dependent regulation of autophagic flux that complemented the polarity and NF-κB branches of PKCι signaling.","evidence":"siRNA knockdown, overexpression, dominant-negative mutants (L485M, P560R), LC3B-II flux assay in U2OS cells","pmids":["26792725"],"confidence":"Medium","gaps":["Direct mTOR pathway substrate of PKCι not identified","Cell-type generalizability not tested beyond U2OS"]},{"year":2020,"claim":"Coordinate amplification of PRKCI, SOX2, and ECT2 on 3q26 was shown to be sufficient—with Trp53 loss—to transform mouse lung basal stem cells into LSCC, and PKCι interaction with RIPK2 was found to enhance NF-κB/JNK/ERK signaling in pancreatic cancer, expanding the oncogenic substrate repertoire of PKCι.","evidence":"Mouse basal stem cell transformation, gene expression profiling; Co-IP of PRKCI–RIPK2, xenograft","pmids":["31968252","37016317"],"confidence":"High","gaps":["ECT2 mechanism downstream of PKCι not molecularly defined","RIPK2 phosphosite not mapped"]},{"year":2022,"claim":"Conditional pancreatic Prkci knockout demonstrated that PKCι is required for autophagy in acinar cells in vivo and that its loss promotes early neoplasia but blocks adenocarcinoma progression, resolving a context-dependent tumor-suppressive versus oncogenic duality for PKCι.","evidence":"Pancreas-specific Prkci KO mouse, KrasG12D epistasis, P62 aggregation/autophagy marker analysis, caerulein pancreatitis","pmids":["35159064"],"confidence":"High","gaps":["Direct autophagy substrate of PKCι in acinar cells not identified","Whether autophagy loss is the sole mechanism blocking PDAC progression unclear"]},{"year":2025,"claim":"A series of studies identified three new direct PKCι substrates—TGFβR1 (stabilized against proteasomal degradation), c-Myc (Ser21 phosphorylation prevents ubiquitination), and Jak2 (Ser633 phosphorylation activates STAT3/VEGFA)—collectively explaining PKCι's roles in EMT, proliferation, and angiogenesis in colorectal cancer.","evidence":"In vitro kinase assays with site-directed mutagenesis, ubiquitination assays, endothelial tube formation, Prkci KO xenograft models","pmids":["40382656","41188443","40840329"],"confidence":"Medium","gaps":["All three substrates reported by a single group; independent replication needed","Structural basis of substrate recognition not determined","Relative contribution of each substrate to in vivo tumor phenotype not dissected"]},{"year":2025,"claim":"Rare loss-of-function PRKCI variants were identified as a cause of Van der Woude syndrome, with epistasis experiments placing PKCι upstream of IRF6 in the periderm differentiation program required for palatal fusion—the first Mendelian disease linked to PRKCI.","evidence":"Human genetic analysis of de novo variants, zebrafish functional validation of three alleles, phosphomimetic IRF6 rescue","pmids":["40902599"],"confidence":"High","gaps":["Direct phosphorylation of IRF6 by PKCι not demonstrated","Genotype-phenotype spectrum across additional VWS families not established"]},{"year":null,"claim":"Key unresolved questions include the full repertoire of direct PKCι substrates in polarity and autophagy contexts, the structural basis for PKCι substrate selectivity versus PKCζ, and whether the recently identified oncogenic substrates (TGFβR1, c-Myc, Jak2) are relevant across cancer types beyond colorectal cancer.","evidence":"","pmids":[],"confidence":"High","gaps":["No crystal structure of full-length PKCι in complex with a substrate","Isoform-specific (ι vs. ζ) substrate selectivity mechanism unknown","Therapeutic window for PKCι inhibition in cancer vs. normal polarity not defined"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[0,2,10,23,24,25]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[0,2,10,23,24,25]}],"localization":[{"term_id":"GO:0005886","term_label":"plasma membrane","supporting_discovery_ids":[4,5]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[11,20]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[2,3,13,16,25]},{"term_id":"R-HSA-1500931","term_label":"Cell-Cell communication","supporting_discovery_ids":[4,5,22]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[2,3,13]},{"term_id":"R-HSA-9612973","term_label":"Autophagy","supporting_discovery_ids":[11,17]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[7,8,21]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[10,15,19,23,24,25]}],"complexes":["PAR3–PAR6–aPKC polarity complex","p62–RIP–aPKC NF-κB signaling complex"],"partners":["PARD6B","PARD3","CDC42","SQSTM1","RIPK1","SOX2","RIPK2","IKBKB"],"other_free_text":[]},"mechanistic_narrative":"PRKCI encodes protein kinase C iota, an atypical serine/threonine kinase that functions as the catalytic component of the evolutionarily conserved PAR3–PAR6–aPKC polarity complex, where it is essential for establishing apicobasal epithelial polarity, tight junction biogenesis, oriented cell division, and tissue morphogenesis in contexts ranging from cardiac development to neural progenitor self-renewal [PMID:10934474, PMID:11257119, PMID:16319113, PMID:19449304]. Through its PB1 domain, PKCι scaffolds with p62/SQSTM1 and RIP to activate NF-κB by directly phosphorylating IKKβ at Ser177/Ser181, and it sustains autophagy flux via the PIK3CA/AKT–mTOR axis in pancreatic acinar cells [PMID:10022904, PMID:10356400, PMID:35159064]. In oncogenic settings, PKCι phosphorylates SOX2 to drive Hedgehog ligand production, stabilizes c-Myc (Ser21) and TGFβR1 against proteasomal degradation, and phosphorylates Jak2 (Ser633) to promote STAT3-dependent angiogenesis [PMID:24525231, PMID:41188443, PMID:40382656, PMID:40840329]. Rare loss-of-function PRKCI variants cause Van der Woude syndrome by disrupting periderm differentiation upstream of IRF6 [PMID:40902599]."},"prefetch_data":{"uniprot":{"accession":"P41743","full_name":"Protein kinase C iota type","aliases":["Atypical protein kinase C-lambda/iota","PRKC-lambda/iota","aPKC-lambda/iota","nPKC-iota"],"length_aa":596,"mass_kda":68.3,"function":"Calcium- and diacylglycerol-independent serine/ threonine-protein kinase that plays a general protective role against apoptotic stimuli, is involved in NF-kappa-B activation, cell survival, differentiation and polarity, and contributes to the regulation of microtubule dynamics in the early secretory pathway. Is necessary for BCR-ABL oncogene-mediated resistance to apoptotic drug in leukemia cells, protecting leukemia cells against drug-induced apoptosis. In cultured neurons, prevents amyloid beta protein-induced apoptosis by interrupting cell death process at a very early step. In glioblastoma cells, may function downstream of phosphatidylinositol 3-kinase (PI(3)K) and PDPK1 in the promotion of cell survival by phosphorylating and inhibiting the pro-apoptotic factor BAD. Can form a protein complex in non-small cell lung cancer (NSCLC) cells with PARD6A and ECT2 and regulate ECT2 oncogenic activity by phosphorylation, which in turn promotes transformed growth and invasion. In response to nerve growth factor (NGF), acts downstream of SRC to phosphorylate and activate IRAK1, allowing the subsequent activation of NF-kappa-B and neuronal cell survival. Functions in the organization of the apical domain in epithelial cells by phosphorylating EZR. This step is crucial for activation and normal distribution of EZR at the early stages of intestinal epithelial cell differentiation. Forms a protein complex with LLGL1 and PARD6B independently of PARD3 to regulate epithelial cell polarity. Plays a role in microtubule dynamics in the early secretory pathway through interaction with RAB2A and GAPDH and recruitment to vesicular tubular clusters (VTCs). In human coronary artery endothelial cells (HCAEC), is activated by saturated fatty acids and mediates lipid-induced apoptosis. Involved in early synaptic long term potentiation phase in CA1 hippocampal cells and short term memory formation (By similarity)","subcellular_location":"Cytoplasm; Membrane; Endosome; Nucleus","url":"https://www.uniprot.org/uniprotkb/P41743/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/PRKCI","classification":"Not Classified","n_dependent_lines":72,"n_total_lines":1208,"dependency_fraction":0.059602649006622516},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000163558","cell_line_id":"CID001247","localizations":[{"compartment":"cytoplasmic","grade":3},{"compartment":"nucleoplasm","grade":3}],"interactors":[{"gene":"PARD6B","stoichiometry":10.0},{"gene":"LLGL1","stoichiometry":10.0},{"gene":"LLGL2","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001247","total_profiled":1310},"omim":[{"mim_id":"616850","title":"WD REPEAT-CONTAINING PROTEIN 83; WDR83","url":"https://www.omim.org/entry/616850"},{"mim_id":"609737","title":"CRUMBS CELL POLARITY COMPLEX COMPONENT 3; CRB3","url":"https://www.omim.org/entry/609737"},{"mim_id":"607484","title":"PAR6 FAMILY CELL POLARITY REGULATOR ALPHA; PARD6A","url":"https://www.omim.org/entry/607484"},{"mim_id":"607032","title":"SMG1 NONSENSE-MEDIATED mRNA DECAY-ASSOCIATED PI3K-RELATED KINASE; SMG1","url":"https://www.omim.org/entry/607032"},{"mim_id":"600539","title":"PROTEIN KINASE C, IOTA FORM; PRKCI","url":"https://www.omim.org/entry/600539"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Cytosol","reliability":"Supported"},{"location":"Microtubules","reliability":"Additional"},{"location":"Cytokinetic bridge","reliability":"Additional"},{"location":"Primary cilium","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/PRKCI"},"hgnc":{"alias_symbol":["PKCI"],"prev_symbol":["DXS1179E"]},"alphafold":{"accession":"P41743","domains":[{"cath_id":"3.10.20.90","chopping":"25-138","consensus_level":"high","plddt":83.9658,"start":25,"end":138},{"cath_id":"3.30.200.20","chopping":"250-334_544-590","consensus_level":"high","plddt":89.1979,"start":250,"end":590},{"cath_id":"1.10.510.10","chopping":"339-531","consensus_level":"high","plddt":93.2159,"start":339,"end":531}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P41743","model_url":"https://alphafold.ebi.ac.uk/files/AF-P41743-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P41743-F1-predicted_aligned_error_v6.png","plddt_mean":80.31},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=PRKCI","jax_strain_url":"https://www.jax.org/strain/search?query=PRKCI"},"sequence":{"accession":"P41743","fasta_url":"https://rest.uniprot.org/uniprotkb/P41743.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P41743/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P41743"}},"corpus_meta":[{"pmid":"24525231","id":"PMC_24525231","title":"The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate Hedgehog signaling in lung squamous cell carcinoma.","date":"2014","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/24525231","citation_count":250,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33234130","id":"PMC_33234130","title":"circPARD3 drives malignant progression and chemoresistance of laryngeal squamous cell carcinoma by inhibiting autophagy through the PRKCI-Akt-mTOR pathway.","date":"2020","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/33234130","citation_count":142,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11877379","id":"PMC_11877379","title":"Stability of a PKCI-1-related mRNA is controlled by the splicing factor ASF/SF2: a novel function for SR proteins.","date":"2002","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/11877379","citation_count":120,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11029061","id":"PMC_11029061","title":"Wpkci, encoding an altered form of PKCI, is conserved widely on the avian W chromosome and expressed in early female embryos: implication of its role in female sex determination.","date":"2000","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/11029061","citation_count":113,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28698296","id":"PMC_28698296","title":"PRKCI promotes immune suppression in ovarian cancer.","date":"2017","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/28698296","citation_count":78,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16319113","id":"PMC_16319113","title":"Heart and soul/PRKCi and nagie oko/Mpp5 regulate myocardial coherence and remodeling during cardiac morphogenesis.","date":"2005","source":"Development (Cambridge, England)","url":"https://pubmed.ncbi.nlm.nih.gov/16319113","citation_count":71,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17990328","id":"PMC_17990328","title":"Amplification of PRKCI, located in 3q26, is associated with lymph node metastasis in esophageal squamous cell carcinoma.","date":"2008","source":"Genes, chromosomes & cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17990328","citation_count":64,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9770345","id":"PMC_9770345","title":"Characterization of PKCI and comparative studies with FHIT, related members of the HIT protein family.","date":"1998","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/9770345","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19912621","id":"PMC_19912621","title":"Anti-depressant and anxiolytic like behaviors in PKCI/HINT1 knockout mice associated with elevated plasma corticosterone level.","date":"2009","source":"BMC neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/19912621","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10958787","id":"PMC_10958787","title":"Interactions of Cdk7 and Kin28 with Hint/PKCI-1 and Hnt1 histidine triad proteins.","date":"2000","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/10958787","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17126529","id":"PMC_17126529","title":"RGSZ1 interacts with protein kinase C interacting protein PKCI-1 and modulates mu opioid receptor signaling.","date":"2006","source":"Cellular signalling","url":"https://pubmed.ncbi.nlm.nih.gov/17126529","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28905214","id":"PMC_28905214","title":"miR-217-5p induces apoptosis by directly targeting PRKCI, BAG3, ITGAV and MAPK1 in colorectal cancer cells.","date":"2017","source":"Journal of cell communication and signaling","url":"https://pubmed.ncbi.nlm.nih.gov/28905214","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30659640","id":"PMC_30659640","title":"Circular RNA circ-PRKCI functions as a competitive endogenous RNA to regulate AKT3 expression by sponging miR-3680-3p in esophageal squamous cell carcinoma.","date":"2019","source":"Journal of cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/30659640","citation_count":45,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"18270824","id":"PMC_18270824","title":"Distribution and expression of protein kinase C interactive protein (PKCI/HINT1) in mouse central nervous system (CNS).","date":"2008","source":"Neurochemical research","url":"https://pubmed.ncbi.nlm.nih.gov/18270824","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31968252","id":"PMC_31968252","title":"Chromosome 3q26 Gain Is an Early Event Driving Coordinated Overexpression of the PRKCI, SOX2, and ECT2 Oncogenes in Lung Squamous Cell Carcinoma.","date":"2020","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/31968252","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32739469","id":"PMC_32739469","title":"Circular RNA PRKCI silencing represses esophageal cancer progression and elevates cell radiosensitivity through regulating the miR-186-5p/PARP9 axis.","date":"2020","source":"Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32739469","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31409777","id":"PMC_31409777","title":"Circular RNA PRKCI promotes glioma cell progression by inhibiting microRNA-545.","date":"2019","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/31409777","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28070856","id":"PMC_28070856","title":"MiR-29c/PRKCI Regulates Axonal Growth of Dorsal Root Ganglia Neurons Under Hyperglycemia.","date":"2017","source":"Molecular neurobiology","url":"https://pubmed.ncbi.nlm.nih.gov/28070856","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32820156","id":"PMC_32820156","title":"Addiction to protein kinase Cɩ due to PRKCI gene amplification can be exploited for an aptamer-based targeted therapy in ovarian cancer.","date":"2020","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32820156","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33880589","id":"PMC_33880589","title":"circ-PRKCI targets miR-1294 and miR-186-5p by downregulating FOXK1 expression to suppress glycolysis in hepatocellular carcinoma.","date":"2021","source":"Molecular medicine reports","url":"https://pubmed.ncbi.nlm.nih.gov/33880589","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31086464","id":"PMC_31086464","title":"Role and mechanism of circ-PRKCI in hepatocellular carcinoma.","date":"2019","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/31086464","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8812426","id":"PMC_8812426","title":"Cloning, mapping, and in vivo localization of a human member of the PKCI-1 protein family (PRKCNH1).","date":"1996","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/8812426","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29895226","id":"PMC_29895226","title":"Down-regulation of circ-PRKCI inhibits cell migration and proliferation in Hirschsprung disease by suppressing the expression of miR-1324 target PLCB1.","date":"2018","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/29895226","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33716239","id":"PMC_33716239","title":"Silencing circRNA protein kinase C iota (circ-PRKCI) suppresses cell progression and glycolysis of human papillary thyroid cancer through circ-PRKCI/miR-335/E2F3 ceRNA axis.","date":"2021","source":"Endocrine journal","url":"https://pubmed.ncbi.nlm.nih.gov/33716239","citation_count":20,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"1599424","id":"PMC_1599424","title":"Purification of PKC-I, an endogenous protein kinase C inhibitor, and types II and III protein kinase C isoenzymes from human neutrophils.","date":"1992","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/1599424","citation_count":19,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36612120","id":"PMC_36612120","title":"Tumor Cell-Derived Exosomal circ-PRKCI Promotes Proliferation of Renal Cell Carcinoma via Regulating miR-545-3p/CCND1 Axis.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/36612120","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25356169","id":"PMC_25356169","title":"miR-219 inhibits the growth and metastasis of TSCC cells by targeting PRKCI.","date":"2014","source":"International journal of clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25356169","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11173133","id":"PMC_11173133","title":"Effect of protein kinase C inhibitor (PKCI) on radiation sensitivity and c-fos transcription.","date":"2001","source":"International journal of radiation oncology, biology, physics","url":"https://pubmed.ncbi.nlm.nih.gov/11173133","citation_count":18,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37016317","id":"PMC_37016317","title":"Paired protein kinases PRKCI-RIPK2 promote pancreatic cancer growth and metastasis via enhancing NF-κB/JNK/ERK phosphorylation.","date":"2023","source":"Molecular medicine (Cambridge, Mass.)","url":"https://pubmed.ncbi.nlm.nih.gov/37016317","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26475383","id":"PMC_26475383","title":"Association of polymorphisms in PRKCI gene and risk of prostate cancer in a sample of Iranian Population.","date":"2015","source":"Cellular and molecular biology (Noisy-le-Grand, France)","url":"https://pubmed.ncbi.nlm.nih.gov/26475383","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26792725","id":"PMC_26792725","title":"PRKCI negatively regulates autophagy via PIK3CA/AKT-MTOR signaling.","date":"2016","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/26792725","citation_count":17,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28844109","id":"PMC_28844109","title":"Intratumoral Heterogeneity of Somatic Mutations for NRIP1, DOK1, ULK1, ULK2, DLGAP3, PARD3 and PRKCI in Colon Cancers.","date":"2017","source":"Pathology oncology research : POR","url":"https://pubmed.ncbi.nlm.nih.gov/28844109","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29228547","id":"PMC_29228547","title":"Integrated genomic analysis of clear cell ovarian cancers identified PRKCI as a potential therapeutic target.","date":"2017","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/29228547","citation_count":15,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35159064","id":"PMC_35159064","title":"Prkci Regulates Autophagy and Pancreatic Tumorigenesis in Mice.","date":"2022","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/35159064","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32985287","id":"PMC_32985287","title":"Circular RNA PRKCI and microRNA-545 relate to sepsis risk, disease severity and 28-day mortality.","date":"2020","source":"Scandinavian journal of clinical and laboratory investigation","url":"https://pubmed.ncbi.nlm.nih.gov/32985287","citation_count":14,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31773680","id":"PMC_31773680","title":"Circular RNA circ-PRKCI promotes cell proliferation and invasion by binding to microRNA-545 in gastric cancer.","date":"2019","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/31773680","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16428323","id":"PMC_16428323","title":"PKCI-W forms a heterodimer with PKCI-Z and inhibits the biological activities of PKCI-Z in vitro, supporting the predicted role of PKCI-W in sex determination in birds.","date":"2006","source":"Journal of biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16428323","citation_count":13,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35260606","id":"PMC_35260606","title":"Impact of deleterious missense PRKCI variants on structural and functional dynamics of protein.","date":"2022","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/35260606","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34269703","id":"PMC_34269703","title":"Circ-PRKCI Alleviates Lipopolysaccharide-induced Human Kidney 2 Cell Injury by Regulating miR-106b-5p/GAB1 Axis.","date":"2021","source":"Journal of cardiovascular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/34269703","citation_count":12,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35675330","id":"PMC_35675330","title":"Identification of Arhgef12 and Prkci as genetic modifiers of retinal dysplasia in the Crb1rd8 mouse model.","date":"2022","source":"PLoS genetics","url":"https://pubmed.ncbi.nlm.nih.gov/35675330","citation_count":11,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19449304","id":"PMC_19449304","title":"Apical polarity protein PrkCi is necessary for maintenance of spinal cord precursors in zebrafish.","date":"2009","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/19449304","citation_count":10,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35785194","id":"PMC_35785194","title":"PRKCI Mediates Radiosensitivity via the Hedgehog/GLI1 Pathway in Cervical Cancer.","date":"2022","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35785194","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32686580","id":"PMC_32686580","title":"The interplay between PRKCI/PKCλ/ι, SQSTM1/p62, and autophagy orchestrates the oxidative metabolic response that drives liver cancer.","date":"2020","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/32686580","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"22768194","id":"PMC_22768194","title":"In vivo conditions to identify Prkci phosphorylation targets using the analog-sensitive kinase method in zebrafish.","date":"2012","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/22768194","citation_count":9,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24510606","id":"PMC_24510606","title":"Two novel PRKCI polymorphisms and prostate cancer risk in an Eastern Chinese Han population.","date":"2014","source":"Molecular carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/24510606","citation_count":6,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33155212","id":"PMC_33155212","title":"Circular RNA circ-PRKCI promotes lung cancer progression by binding to microRNA-1324 to regulate MECP2 expression.","date":"2020","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/33155212","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39529141","id":"PMC_39529141","title":"miR-630 as a therapeutic target in pancreatic cancer stem cells: modulation of the PRKCI-Hedgehog signaling axis.","date":"2024","source":"Biology direct","url":"https://pubmed.ncbi.nlm.nih.gov/39529141","citation_count":5,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39015499","id":"PMC_39015499","title":"Downregulation of PRKCI inhibits osteosarcoma cell growth by inactivating the Akt/mTOR signaling pathway.","date":"2024","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/39015499","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38741779","id":"PMC_38741779","title":"Circular RNA PRKCI (hsa_circ_0067934): a potential target in the pathogenesis of human malignancies.","date":"2024","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/38741779","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10555761","id":"PMC_10555761","title":"HIT family genes: FHIT but not PKCI-1/HINT produces altered transcripts in colorectal cancer.","date":"1999","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10555761","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11978974","id":"PMC_11978974","title":"The assignment of PRKCI to bovine chromosome 1q34-->q36 by FISH suggests a new assignment to human chromosome 3.","date":"2001","source":"Cytogenetics and cell genetics","url":"https://pubmed.ncbi.nlm.nih.gov/11978974","citation_count":4,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40386233","id":"PMC_40386233","title":"Has_circRNA_0122683 (circ-PRKCI) relieves ferroptosis of HPAEpiCs in sepsis-induced acute lung injury by sponging miR-382-5p.","date":"2025","source":"PeerJ","url":"https://pubmed.ncbi.nlm.nih.gov/40386233","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34895031","id":"PMC_34895031","title":"Immunosurveillance, interferon, and autophagic networking in cancer: the PRKCI-ULK2 paradigm.","date":"2021","source":"Autophagy","url":"https://pubmed.ncbi.nlm.nih.gov/34895031","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36833174","id":"PMC_36833174","title":"Investigation of UTR Variants by Computational Approaches Reveal Their Functional Significance in PRKCI Gene Regulation.","date":"2023","source":"Genes","url":"https://pubmed.ncbi.nlm.nih.gov/36833174","citation_count":3,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40902599","id":"PMC_40902599","title":"Rare variants in PRKCI cause Van der Woude syndrome and other features of peridermopathy.","date":"2025","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/40902599","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39922422","id":"PMC_39922422","title":"MK886 ameliorates Alzheimer's disease by activating the PRKCI/AKT signaling pathway.","date":"2025","source":"European journal of pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/39922422","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40001200","id":"PMC_40001200","title":"The PAR6B-PRKCI-PAR3 complex influences alveolar regeneration in patients with the emphysema subtype of chronic obstructive pulmonary disease.","date":"2025","source":"Stem cell research & therapy","url":"https://pubmed.ncbi.nlm.nih.gov/40001200","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40100546","id":"PMC_40100546","title":"Unravelling the role of PRKCI and key-cancer related genes in breast cancer development and metastasis.","date":"2025","source":"Discover oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40100546","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27312576","id":"PMC_27312576","title":"Prkci is required for a non-autonomous signal that coordinates cell polarity during cavitation.","date":"2016","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/27312576","citation_count":2,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40382656","id":"PMC_40382656","title":"Prkci promotes colorectal cancer metastasis by phosphorylating and stabilizing Tgfbr1 to activate TGF-β signaling.","date":"2025","source":"Cell communication and signaling : CCS","url":"https://pubmed.ncbi.nlm.nih.gov/40382656","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39867391","id":"PMC_39867391","title":"Rare variants in PRKCI cause Van der Woude syndrome and other features of peridermopathy.","date":"2025","source":"medRxiv : the preprint server for health sciences","url":"https://pubmed.ncbi.nlm.nih.gov/39867391","citation_count":1,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40840329","id":"PMC_40840329","title":"Prkci activates Jak2/Stat3 signaling to promote tumor angiogenesis: Short Name: Prkci in tumor angiogenesis.","date":"2025","source":"Neoplasia (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/40840329","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40692866","id":"PMC_40692866","title":"Correction: Downregulation of PRKCI inhibits osteosarcoma cell growth by inactivating the Akt/mTOR signaling pathway.","date":"2025","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/40692866","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41188443","id":"PMC_41188443","title":"Prkci acts a pro-proliferation factor in colorectal cancer.","date":"2025","source":"NPJ precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/41188443","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41608557","id":"PMC_41608557","title":"Correction: PRKCI mediates radiosensitivity via the Hedgehog/GLI1 pathway in cervical cancer.","date":"2026","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/41608557","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"41530882","id":"PMC_41530882","title":"Circ-PRKCI attenuates acute lung injury secondary to sepsis by targeting the miR-106b-5p/GAB1 axis.","date":"2026","source":"European journal of medical research","url":"https://pubmed.ncbi.nlm.nih.gov/41530882","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35113408","id":"PMC_35113408","title":"Author Correction: Circular RNA circ-PRKCI promotes cell proliferation and invasion by binding to microRNA-545 in gastric cancer.","date":"2022","source":"European review for medical and pharmacological sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35113408","citation_count":0,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2025.01.13.632869","title":"The nucleocytoplasmic translocation of HINT1 regulates the maturation of cell density","date":"2025-01-14","source":"bioRxiv","url":"https://doi.org/10.1101/2025.01.13.632869","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":null,"id":"bio_10.1101_2024.05.22.595312","title":"Functional roles of neural aPKCs in mouse brain development and survival","date":"2024-05-23","source":"bioRxiv","url":"https://doi.org/10.1101/2024.05.22.595312","citation_count":0,"is_preprint":true,"source_track":"pubmed_title"},{"pmid":"16189514","id":"PMC_16189514","title":"Towards a proteome-scale map of the human protein-protein interaction network.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16189514","citation_count":2090,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20562859","id":"PMC_20562859","title":"Network organization of the human autophagy system.","date":"2010","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/20562859","citation_count":1286,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19615732","id":"PMC_19615732","title":"Defining the human deubiquitinating enzyme interaction landscape.","date":"2009","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/19615732","citation_count":1282,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25416956","id":"PMC_25416956","title":"A proteome-scale map of the human interactome network.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25416956","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10934474","id":"PMC_10934474","title":"The cell-polarity protein Par6 links Par3 and atypical protein kinase C to Cdc42.","date":"2000","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/10934474","citation_count":761,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939624","id":"PMC_22939624","title":"Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939624","citation_count":708,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"19056867","id":"PMC_19056867","title":"Large-scale proteomics and phosphoproteomics of urinary exosomes.","date":"2008","source":"Journal of the American Society of Nephrology : JASN","url":"https://pubmed.ncbi.nlm.nih.gov/19056867","citation_count":607,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29395067","id":"PMC_29395067","title":"High-Density Proximity Mapping Reveals the Subcellular Organization of mRNA-Associated Granules and Bodies.","date":"2018","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/29395067","citation_count":580,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15489334","id":"PMC_15489334","title":"The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).","date":"2004","source":"Genome research","url":"https://pubmed.ncbi.nlm.nih.gov/15489334","citation_count":438,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26638075","id":"PMC_26638075","title":"A Dynamic Protein Interaction Landscape of the Human Centrosome-Cilium Interface.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26638075","citation_count":433,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"35271311","id":"PMC_35271311","title":"OpenCell: Endogenous tagging for the cartography of human cellular organization.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35271311","citation_count":432,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"20360068","id":"PMC_20360068","title":"Systematic analysis of human protein complexes identifies chromosome segregation proteins.","date":"2010","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/20360068","citation_count":421,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26344197","id":"PMC_26344197","title":"Panorama of ancient metazoan macromolecular complexes.","date":"2015","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/26344197","citation_count":407,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24255178","id":"PMC_24255178","title":"Protein interaction network of the mammalian Hippo pathway reveals mechanisms of kinase-phosphatase interactions.","date":"2013","source":"Science signaling","url":"https://pubmed.ncbi.nlm.nih.gov/24255178","citation_count":383,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"11257119","id":"PMC_11257119","title":"Atypical protein kinase C is involved in the evolutionarily conserved par protein complex and plays a critical role in establishing epithelia-specific junctional structures.","date":"2001","source":"The Journal of cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/11257119","citation_count":378,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10356400","id":"PMC_10356400","title":"The interaction of p62 with RIP links the atypical PKCs to NF-kappaB activation.","date":"1999","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/10356400","citation_count":344,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"34079125","id":"PMC_34079125","title":"A proximity-dependent biotinylation map of a human cell.","date":"2021","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/34079125","citation_count":339,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8797824","id":"PMC_8797824","title":"The product of par-4, a gene induced during apoptosis, interacts selectively with the atypical isoforms of protein kinase C.","date":"1996","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/8797824","citation_count":325,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12813044","id":"PMC_12813044","title":"Interaction codes within the family of mammalian Phox and Bem1p domain-containing proteins.","date":"2003","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/12813044","citation_count":322,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10022904","id":"PMC_10022904","title":"Activation of IkappaB kinase beta by protein kinase C isoforms.","date":"1999","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/10022904","citation_count":310,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8226978","id":"PMC_8226978","title":"Molecular cloning and characterization of PKC iota, an atypical isoform of protein kinase C derived from insulin-secreting cells.","date":"1993","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8226978","citation_count":310,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16678097","id":"PMC_16678097","title":"A Rich1/Amot complex regulates the Cdc42 GTPase and apical-polarity proteins in epithelial cells.","date":"2006","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16678097","citation_count":302,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"31006538","id":"PMC_31006538","title":"Intrinsically Disordered Protein TEX264 Mediates ER-phagy.","date":"2019","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/31006538","citation_count":296,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":35396,"output_tokens":5180,"usd":0.091944},"stage2":{"model":"claude-opus-4-6","input_tokens":8787,"output_tokens":2957,"usd":0.17679},"total_usd":0.607106,"stage1_batch_id":"msgbatch_01SUR8NDzVrNmyszWyJeCct7","stage2_batch_id":"msgbatch_01G7Yfutko3cDWzejrwH5AMx","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":47816,"output_tokens":7398,"usd":0.127209},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":10885,"output_tokens":3454,"usd":0.211163}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2014,\n      \"finding\": \"PKCι (PRKCI) phosphorylates SOX2 and recruits it to the promoter of Hedgehog acyltransferase (HHAT), driving HHAT expression and establishing a cell-autonomous Hedgehog signaling axis in lung squamous cell carcinoma; PKCι-mediated SOX2 phosphorylation is required for HHAT promoter occupancy.\",\n      \"method\": \"Co-immunoprecipitation, promoter occupancy assays (ChIP), phosphorylation assays, loss-of-function in vitro and in vivo\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, ChIP, functional rescue, multiple orthogonal methods in single high-impact study\",\n      \"pmids\": [\"24525231\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PRKCI oncogenic activity in ovarian cancer involves upregulation of TNFα to promote an immune-suppressive tumor microenvironment, and YAP1 is identified as a downstream effector of PRKCI in tumor progression.\",\n      \"method\": \"Transgenic mouse models, functional analyses, system-level pathway analysis, loss-of-function\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo transgenic model with mechanistic follow-up, single lab\",\n      \"pmids\": [\"28698296\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Zebrafish Heart and soul/PRKCi is required tissue-autonomously within the myocardium for cardiac morphogenesis dependent on its catalytic activity, and functions with Nagie oko/Mpp5 to maintain polarized epithelial organization and coherence of myocardial cells during heart cone formation.\",\n      \"method\": \"Genetic mosaic analysis, catalytic-dead mutant rescue, tissue-specific rescue experiments in zebrafish\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis, catalytic mutant, tissue-autonomous rescue; strong mechanistic evidence\",\n      \"pmids\": [\"16319113\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"CDK7 physically interacts with Hint/PKCI-1; overexpression of Cdk7 causes partial relocalization of Hint to the nucleus; the interaction is independent of cyclin H binding or Cdk7 kinase activity; genetic interaction between yeast orthologs KIN28 and HNT1 was demonstrated by synthetic growth defects.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, subcellular localization studies, yeast double-mutant epistasis\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP confirmed two-hybrid, plus genetic epistasis in yeast; moderate, single lab\",\n      \"pmids\": [\"10958787\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"RGSZ1 interacts with PKCI-1 (confirmed by yeast two-hybrid, co-immunoprecipitation, and immunofluorescence); PKCI-1 interacts with the mu opioid receptor and suppresses receptor desensitization and PKC-related mu opioid receptor phosphorylation; PKCI-1 combined with RGSZ1 enhances inhibition of cAMP by the mu opioid receptor.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, immunofluorescence, cAMP inhibition assay\",\n      \"journal\": \"Cellular signalling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — reciprocal Co-IP plus functional assay, single lab\",\n      \"pmids\": [\"17126529\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PRKCI negatively regulates autophagy through the PIK3CA/AKT-MTOR signaling pathway; PRKCI overexpression impairs autophagy (decreased LC3B-II, reduced autophagic substrate degradation), while PRKCI knockdown promotes autophagy; two novel PRKCI mutants (L485M and P560R) act as dominant negatives and induce autophagy.\",\n      \"method\": \"siRNA knockdown, overexpression, LC3B-II western blot, autophagic flux assay, dominant-negative mutant analysis, pathway inhibition\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple functional assays and mutant analysis, single lab\",\n      \"pmids\": [\"26792725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Pancreas-specific ablation of Prkci in mice causes P62 aggregation, loss of autophagic vesicles, increased acinar cell DNA damage and apoptosis in Prkci-ablated pancreatic acinar cells, and promotes Kras-mediated pancreatic intraepithelial neoplasia but blocks progression to adenocarcinoma, establishing a role for PKCι in pancreatic epithelial cell autophagy.\",\n      \"method\": \"Pancreas-specific conditional knockout mice, immunohistochemistry, autophagic vesicle analysis, Kras-driven tumorigenesis model\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — clean in vivo conditional KO with defined phenotypic readout and pathway placement\",\n      \"pmids\": [\"35159064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PKCι-SOX2 collaboration activates an extensive transcriptional program enforcing a lineage-restricted LSCC phenotype, while PKCι-ECT2 collaboration promotes oncogenic growth; together PRKCI, SOX2, and ECT2 overexpression in the context of Trp53 loss is sufficient to transform mouse lung basal stem cells.\",\n      \"method\": \"Mouse transformation assay, gene expression profiling, in vivo tumor modeling, genetic cooperation analysis\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo transformation with defined genetic interactions, multiple oncogene combinations tested\",\n      \"pmids\": [\"31968252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In zebrafish, loss of PrkCi function causes neural precursor divisions to become oblique during late embryogenesis and results in excess oligodendrocyte formation concomitant with loss of dividing cells, establishing PrkCi as required for planar, asymmetric self-renewing division of spinal cord precursors.\",\n      \"method\": \"Time-lapse imaging, zebrafish loss-of-function (has mutants), cell fate quantification\",\n      \"journal\": \"Developmental dynamics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct live imaging and loss-of-function with defined cellular phenotype, single lab\",\n      \"pmids\": [\"19449304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"An analog-sensitive kinase method was established to identify Prkci substrates in zebrafish in vivo; thiophosphorylation labeling with bulky ATPγS analogs followed by immunoaffinity enrichment of thiophosphopeptides allows substrate identification in the context of vertebrate development.\",\n      \"method\": \"Analog-sensitive kinase method, ATPγS analog labeling, immunoaffinity purification of thiophosphopeptides, mass spectrometry in zebrafish embryo\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — in vivo substrate labeling methodology established; methodology paper, moderate evidence\",\n      \"pmids\": [\"22768194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Prkci is required for producing a non-autonomous polarity signal during cavitation; Prkci-null cells fail to properly segregate apical-basal proteins, form coordinated ectodermal epithelium, or participate in cavitation; mixing with wildtype cells rescues polarity, indicating Prkci is required to produce—but not respond to—non-autonomous polarity cues.\",\n      \"method\": \"Prkci-/- ES cells, mosaic chimera experiments, immunofluorescence for polarity markers, BMP4 and Ezrin overexpression rescue\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic loss-of-function with chimeric rescue and mechanistic interpretation, single lab\",\n      \"pmids\": [\"27312576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"PRKCI physically interacts with RIPK2 (confirmed by co-immunoprecipitation and immunofluorescence) and their interaction enhances phosphorylation of downstream NF-κB, JNK, and ERK in pancreatic cancer cells.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence, western blot for phosphorylation, RIPK2 knockout and overexpression\",\n      \"journal\": \"Molecular medicine (Cambridge, Mass.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — Co-IP plus functional phosphorylation readouts; single lab\",\n      \"pmids\": [\"37016317\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Prkci phosphorylates and stabilizes Tgfbr1 (TGF-β receptor 1), preventing its proteasomal degradation, thereby amplifying TGF-β downstream signaling cascades and promoting epithelial-to-mesenchymal transition and CRC metastasis.\",\n      \"method\": \"Co-immunoprecipitation, phosphorylation assays, proteasomal degradation assays, in vivo mouse metastasis model with Prkci knockout\",\n      \"journal\": \"Cell communication and signaling : CCS\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct phosphorylation assay with substrate stabilization readout and in vivo validation; single lab, recent\",\n      \"pmids\": [\"40382656\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Prkci interacts with and phosphorylates c-Myc at serine 21, inhibiting its ubiquitin-mediated proteasomal degradation and stabilizing the protein; the pro-proliferative effect of Prkci in CRC depends on this c-Myc S21 phosphorylation.\",\n      \"method\": \"Co-immunoprecipitation, phosphorylation site mutagenesis (S21), ubiquitination assay, in vitro and in vivo proliferation assays with Prkci knockout\",\n      \"journal\": \"NPJ precision oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct phosphorylation with site-specific mutagenesis and ubiquitination assay; single lab, recent\",\n      \"pmids\": [\"41188443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Prkci activates the Jak2/Stat3 signaling pathway by phosphorylating Jak2 at serine 633, leading to downstream Stat3 activation, increased VEGFA expression, and promotion of tumor angiogenesis in colorectal cancer.\",\n      \"method\": \"Phosphorylation site identification (S633), western blot, endothelial cell functional assays (tube formation, migration), in vivo xenograft model with Prkci knockout\",\n      \"journal\": \"Neoplasia (New York, N.Y.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — specific phosphorylation site identified with downstream pathway and functional validation; single lab, recent\",\n      \"pmids\": [\"40840329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"PRKCI loss-of-function variants cause Van der Woude syndrome; phosphomimetic IRF6 can rescue aPKC inhibition effects in zebrafish, placing PRKCI upstream of IRF6 in the periderm transcriptional regulatory network; three specific variants (p.Arg130His, p.Asn383Ser, p.Leu385Phe) were confirmed as loss-of-function in zebrafish.\",\n      \"method\": \"Zebrafish functional assay (enveloping layer), epistasis rescue with phosphomimetic Irf6, loss-of-function allele testing\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in zebrafish with functional rescue; replicated across independent patients and alleles\",\n      \"pmids\": [\"40902599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PRKCI functions downstream of the Hedgehog/GLI1 pathway to phosphorylate and activate the transcription factor GLI1, modulating GLI1 relocalization and reducing radiosensitivity in cervical cancer cells.\",\n      \"method\": \"qRT-PCR, western blot, immunofluorescence for GLI1 localization, colony formation, CCK-8, apoptosis assays, xenograft model\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — localization and western blot data; direct phosphorylation not demonstrated biochemically\",\n      \"pmids\": [\"35785194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2048,\n      \"finding\": \"PRKCI interacts with SQSTM1/p62 (confirmed by co-immunoprecipitation); this interaction connects PRKCI to autophagy regulation and oxidative metabolic responses in liver cancer.\",\n      \"method\": \"Co-immunoprecipitation (osteosarcoma study: 39015499; conceptual review for HCC: 32686580)\",\n      \"journal\": \"Frontiers in oncology / Autophagy\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single co-IP in osteosarcoma, reviewed mechanistically for HCC without direct biochemical reconstitution\",\n      \"pmids\": [\"39015499\", \"32686580\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The PAR6B-PRKCI-PAR3 complex in alveolar epithelial type II cells (AEC2s) regulates cell cycle; reduced levels of the PAR3-PARD6B-PRKCI complex arrest AEC2s in G0-G1 phase, impairing their self-proliferation in emphysema-type COPD.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry, 3D spheroid formation from primary mouse AEC2s, cell cycle analysis\",\n      \"journal\": \"Stem cell research & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP with mass spectrometry identification of complex, functional cell cycle readout; single lab\",\n      \"pmids\": [\"40001200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"HINT1/PKCI-1 undergoes nucleocytoplasmic translocation regulated by exportin-1 in response to cell density; at low density it resides in the nucleus binding open chromatin, while at high density it is exported to cytoplasm where it inhibits PKC and remodels the actin cytoskeleton, and its presence is necessary for MARCKS dephosphorylation and mature monolayer formation.\",\n      \"method\": \"Live cell imaging, FRAP, exportin-1 inhibition, MARCKS phosphorylation western blot, HINT1 knockout cells\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct localization with functional consequence, multiple orthogonal methods; preprint, single lab\",\n      \"pmids\": [\"bio_10.1101_2025.01.13.632869\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"In neural progenitors, kinase-inactive PRKCI (expressed in mouse knockin) and ablation of both Prkci and Prkcz identify a critical window in neural progenitor differentiation wherein aPKC kinase activity is indispensable for neurodevelopment.\",\n      \"method\": \"Conditional knockout mice, kinase-inactive knockin mouse, brain histology, organismal viability assessment\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — kinase-dead knockin establishes catalytic requirement; preprint, single lab\",\n      \"pmids\": [\"bio_10.1101_2024.05.22.595312\"],\n      \"is_preprint\": true\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"miR-29c directly targets the 3' UTR of PRKCI mRNA (validated by dual-luciferase assay with site-specific mutation); upregulation of miR-29c under hyperglycemia reduces PRKCI protein levels in DRG neurons and causes axonal growth defects that are reversed by PRKCI knockdown or miR-29c knockdown.\",\n      \"method\": \"Dual-luciferase reporter assay with 3'UTR mutation, siRNA knockdown, western blot, axonal growth measurement in DRG neurons\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2-3 — direct 3'UTR validation with mutagenesis plus functional rescue, single lab\",\n      \"pmids\": [\"28070856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"miR-630 directly targets PRKCI (functional assay confirmed), leading to suppression of the Hedgehog signaling pathway and inhibition of pancreatic cancer stem cell self-renewal and tumorigenicity.\",\n      \"method\": \"Functional miRNA target assay, Hedgehog pathway reporter, PCSC self-renewal assays, murine tumorigenicity models\",\n      \"journal\": \"Biology direct\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — functional assay without detailed biochemical mechanistic follow-up of PRKCI-Hh link; single lab\",\n      \"pmids\": [\"39529141\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"PRKCI (PKCι) is an atypical serine/threonine kinase that functions as a component of the PAR polarity complex to maintain apicobasal epithelial polarity and tissue morphogenesis; in cancer, it acts as an oncogene by phosphorylating substrates including SOX2 (to drive Hedgehog/HHAT transcription), Tgfbr1 (to stabilize TGF-β signaling and promote EMT), c-Myc (at S21 to prevent ubiquitin-mediated degradation), and Jak2 (at S633 to activate Stat3/VEGFA and angiogenesis), while also regulating autophagy via suppression of the PIK3CA/AKT-MTOR axis and interacting with partners including SQSTM1/p62 and RIPK2 to modulate NF-κB/JNK/ERK signaling.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\nI'll classify each paper first, then extract discoveries from KEEP papers only.\n\n**Classification:**\n\n- Papers about PRKCI (protein kinase C iota, atypical PKC, aPKCι): KEEP\n- Papers about PKCI-1/HINT1 (histidine triad protein, a different gene): EXCLUDE (alias collision)\n- Papers about circ-PRKCI (circular RNA from PRKCI locus): EXCLUDE (alt-locus product)\n- Papers about PKCI-W/PKCI-Z (avian sex chromosome genes): EXCLUDE (symbol collision - non-orthologous)\n- General interactome/proteomics papers not specific to PRKCI: EXCLUDE\n\n**KEEP:** 1, 5, 6, 10(partially - Hint/PKCI-1 interaction with Cdk7, but this is HINT1 not PRKCI - EXCLUDE), 15, 18(PRKCI miR-29c - KEEP), 22(PRKCNH1 - different gene - EXCLUDE), 25(PKC-I endogenous inhibitor - different protein - EXCLUDE), 27, 29, 31, 33, 34, 38, 40, 41, 42, 43, 44, 47, 48, 53, 55, 57, 59, 60, 61, 62, 64, 69\n\nFrom curated list: 22(aPKC/Par6/Par3/Cdc42), 23(p62/RIP/aPKC/NF-κB), 25(par-4/atypical PKC), 26(PB1 domain), 27(IKKβ activation), 28(PKC iota cloning)\n\nPapers 2,3,4,7,8,9,10,11,12,13,14,16,17,19,20,21,23,24,26,30,32,35,36,37,39,45,46,49,50,51,52,54,56,58,65,66,67,68 — EXCLUDE\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"PKC iota (PRKCI) was molecularly cloned and characterized as a novel atypical PKC isoform. It encodes a 587-amino acid serine-threonine kinase with greatest homology to PKC zeta (72% overall, 84% in catalytic domain), contains a conserved pseudosubstrate sequence, lacks a Ca2+-binding region, and has only one cysteine-rich zinc finger-like domain. Stable expression in CHO-K1 cells showed a 65 kDa protein with increased kinase activity toward myelin basic protein.\",\n      \"method\": \"cDNA cloning, Northern blot, Western blot, in vitro kinase assay\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — original cloning with biochemical validation of kinase activity\",\n      \"pmids\": [\"8226978\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"The product of the pro-apoptotic par-4 gene specifically interacts with the regulatory domains of atypical PKC isoforms (zeta PKC and lambda/iota PKC), dramatically inhibiting their enzymatic activity. Cotransfection of wild-type (but not kinase-inactive) atypical PKCs abrogated par-4-induced apoptotic morphological changes in NIH-3T3 cells, establishing that atypical PKC activity promotes cell survival downstream of par-4.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, dominant-negative mutagenesis, cell transfection with apoptosis readout\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — reciprocal interaction, kinase-dead mutant rescue, multiple orthogonal methods\",\n      \"pmids\": [\"8797824\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Atypical PKC isoforms (lambda/iota PKC and zeta PKC) activate NF-κB through direct binding and phosphorylation of IKKβ (at Ser177 and Ser181), but not IKKα. Dominant-negative lambda/iota PKC impairs RIP-stimulated NF-κB activation. Recombinant active atypical PKC directly phosphorylates IKKβ in vitro, placing atypical PKCs upstream of IKKβ in the TNFα-NF-κB pathway.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, dominant-negative transfection, site-directed mutagenesis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstituted phosphorylation, mutagenesis of substrate sites, epistasis\",\n      \"pmids\": [\"10022904\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"The aPKC-binding protein p62 selectively interacts with RIP (but not TRAF2), bridging the atypical PKCs to RIP in the TNFα signaling pathway. This establishes a signaling cascade: TNF-R1→TRADD/RIP/p62/aPKCs/IKKβ for NF-κB activation. Dominant-negative lambda/iota PKC impairs RIP-stimulated NF-κB activation, and antisense p62 severely abrogates NF-κB activation.\",\n      \"method\": \"Co-immunoprecipitation, in vitro binding assay, dominant-negative transfection, antisense knockdown, NF-κB reporter assay\",\n      \"journal\": \"The EMBO journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — multiple orthogonal methods, defined pathway position by epistasis\",\n      \"pmids\": [\"10356400\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"Par6 forms a complex with Cdc42-GTP, a human homologue of PAR-3, and the regulatory domains of atypical PKC (including PKCι). This Par6-Par3-aPKC-Cdc42 complex is required for formation of normal tight junctions at epithelial cell-cell contacts, linking Cdc42 polarity signaling to atypical PKC via Par6 as a key adaptor.\",\n      \"method\": \"Yeast two-hybrid, Co-immunoprecipitation, dominant-negative expression, tight junction permeability assay\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal Co-IP, functional tight junction assay, replicated across labs\",\n      \"pmids\": [\"10934474\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Atypical PKC (aPKC, including the iota isoform) is a component of the evolutionarily conserved PAR protein complex (aPKC-ASIP/PAR-3-PAR-6 ternary complex) that localizes to the apical junctional region of MDCK epithelial cells. Overexpression of dominant-negative aPKC causes mislocalization of PAR-3, severely disrupts tight junction biogenesis, increases paracellular ion diffusion, and impairs epithelial apico-basal polarity.\",\n      \"method\": \"Dominant-negative mutagenesis, immunocytochemistry, paracellular diffusion assay, Co-immunoprecipitation\",\n      \"journal\": \"The Journal of cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — dominant-negative with multiple orthogonal functional readouts, replicated\",\n      \"pmids\": [\"11257119\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"The PB1 (Phox and Bem1p) domain mediates interactions between atypical PKCs (lambda/iota and zeta PKC) and scaffold proteins p62 and Par6. Mutation analyses identified critical basic charge cluster residues in aPKC PB1 domains that interact with an acidic loop/helix in p62, establishing molecular basis for aPKC coupling to NF-κB and cell polarity signaling pathways.\",\n      \"method\": \"Mutation analysis, molecular modeling, Co-immunoprecipitation, yeast two-hybrid\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — mutagenesis defining interaction surfaces, multiple interacting pairs tested\",\n      \"pmids\": [\"12813044\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Zebrafish heart and soul (Has)/PRKCi is required tissue-autonomously within the myocardium for normal heart morphogenesis, and this function depends on its catalytic activity. PRKCi and Nok/Mpp5 (Pals1) are required early for polarized epithelial organization and coherence of myocardial cells during heart cone formation, placing PRKCi as essential for apicobasal polarity in cardiac tissue.\",\n      \"method\": \"Genetic rescue (catalytic-dead mutant), tissue-specific mosaic analysis, live imaging, zebrafish mutant phenotype\",\n      \"journal\": \"Development (Cambridge, England)\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — catalytic-dead mutant shows activity dependence, tissue-autonomous rescue\",\n      \"pmids\": [\"16319113\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"In zebrafish spinal cord, loss of PrkCi function causes neural precursor divisions to become oblique during late embryogenesis, resulting in excess oligodendrocyte production and loss of dividing progenitor cells. PrkCi is required for planar cell division orientation and asymmetric self-renewing division of spinal cord precursors, acting through apicobasal polarity maintenance.\",\n      \"method\": \"Time-lapse imaging, zebrafish loss-of-function, cell fate analysis (oligodendrocyte vs. progenitor counting)\",\n      \"journal\": \"Developmental dynamics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — live imaging with defined phenotypic readout in single model organism\",\n      \"pmids\": [\"19449304\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"The analog-sensitive kinase method was adapted for in vivo use in zebrafish embryos to identify PKCι substrates. Analog-sensitive Prkci uniquely thiophosphorylates substrates using bulky ATPγS analogs, enabling enrichment and identification of kinase substrates by immunoaffinity purification of thiophosphopeptides in the developing embryo.\",\n      \"method\": \"Analog-sensitive kinase/chemical genetics, mass spectrometry, thiophosphopeptide immunoaffinity purification in zebrafish\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1 — chemical-genetic substrate identification method; foundational methodology paper without full substrate list\",\n      \"pmids\": [\"22768194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PKCι phosphorylates SOX2 and recruits it to the promoter of Hedgehog acyltransferase (HHAT), the rate-limiting enzyme in Hh ligand production. PKCι-mediated SOX2 phosphorylation is required for HHAT promoter occupancy and HHAT expression, establishing a PKCι-SOX2-HHAT signaling axis that drives a stem-like phenotype in lung squamous cell carcinoma. PRKCI and SOX2 are coamplified on chromosome 3q26.\",\n      \"method\": \"In vitro kinase assay (PKCι phosphorylates SOX2), chromatin immunoprecipitation (promoter occupancy), siRNA knockdown, reporter assay, mouse tumor model\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 — direct phosphorylation demonstrated in vitro, ChIP for promoter occupancy, multiple functional readouts\",\n      \"pmids\": [\"24525231\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"PRKCI overexpression impairs functional autophagy in U2OS cells, as evidenced by decreased LC3B-II levels and reduced degradation of autophagic substrates. Conversely, PRKCI knockdown induces autophagy. Two novel dominant-negative PRKCI mutants (L485M and P560R) also induce autophagy. Mechanistically, PRKCI knockdown-mediated autophagy is associated with inactivation of the PIK3CA/AKT-MTOR signaling pathway.\",\n      \"method\": \"siRNA knockdown, overexpression, site-directed mutagenesis, LC3B-II western blot, autophagic flux assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — KD/KO with defined molecular readout and pathway identification, single lab\",\n      \"pmids\": [\"26792725\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"Prkci is required for non-autonomous polarity cue production during cavitation in embryoid bodies. Prkci-null cells fail to properly segregate apical-basal proteins and cannot form a coordinated ectodermal epithelium. When mixed with wildtype cells, cavitation is rescued, indicating Prkci is required to produce (not respond to) non-autonomous polarity cues. Neither BMP4 nor EZRIN overexpression fully rescues the polarized epithelium.\",\n      \"method\": \"Knockout ES cells, chimeric embryoid bodies, live imaging, immunofluorescence, BMP4/EZRIN rescue experiments\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis via chimeric rescue, defined non-autonomous role\",\n      \"pmids\": [\"27312576\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PRKCI promotes immune suppression in ovarian cancer by upregulating TNFα to generate a myeloid-derived suppressor cell-enriched, cytotoxic T-cell-depleted tumor microenvironment. YAP1 was identified as a downstream effector of PRKCI in ovarian tumor progression, establishing a PRKCI-YAP1 signaling axis in immune evasion.\",\n      \"method\": \"Transgenic mouse model, cytokine measurement, immune cell profiling (MDSC/T-cell quantification), siRNA knockdown, system-level analysis\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — transgenic model with functional immune phenotype, pathway placement via YAP1\",\n      \"pmids\": [\"28698296\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"PRKCI is a direct target of miR-29c in dorsal root ganglia neurons. High glucose upregulates miR-29c which reduces PRKCI protein, impairing axonal growth. Knockdown of endogenous miR-29c restores PRKCI protein and axonal growth under high glucose. Knockdown of PRKCI itself under normal glucose inhibits axonal growth, establishing PRKCI as a positive regulator of axonal growth in DRG neurons.\",\n      \"method\": \"Dual-luciferase 3'UTR reporter assay, siRNA knockdown, Western blot, axonal growth measurement in DRG neurons\",\n      \"journal\": \"Molecular neurobiology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — direct 3'UTR validation, siRNA rescue, defined cellular phenotype\",\n      \"pmids\": [\"28070856\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Chromosome 3q26 copy number gains occur early in LSCC tumorigenesis and drive coordinate overexpression of PRKCI, SOX2, and ECT2. PRKCI and SOX2 collaborate to activate a transcriptional program enforcing LSCC lineage, while PRKCI and ECT2 collaborate to promote oncogenic growth. Overexpression of all three oncogenes with Trp53 loss transforms mouse lung basal stem cells into histological LSCC.\",\n      \"method\": \"Mouse transformation model (basal stem cell), genomic analysis, gene expression profiling, siRNA knockdown, mouse tumor formation\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo transformation model, multiple oncogene combinations tested, defined transcriptional program\",\n      \"pmids\": [\"31968252\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"PKCι interacts with RIPK2 kinase in pancreatic cancer cells, as demonstrated by co-immunoprecipitation and immunofluorescence. The PRKCI-RIPK2 complex enhances phosphorylation of downstream NF-κB, JNK, and ERK signaling. RIPK2 knockout inhibits subcutaneous tumor growth and liver metastasis of pancreatic cancer and suppresses autophagosome formation while increasing ROS and apoptosis.\",\n      \"method\": \"Co-immunoprecipitation, immunofluorescence, RIPK2 knockout (in vitro and xenograft), phosphorylation analysis by Western blot\",\n      \"journal\": \"Molecular medicine (Cambridge, Mass.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — Co-IP interaction, in vivo xenograft, multiple signaling readouts; single lab\",\n      \"pmids\": [\"37016317\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"Pancreas-specific Prkci knockout increases acinar cell DNA damage, apoptosis, immune cell infiltration, and causes P62 aggregation with loss of autophagic vesicles, establishing PKCι as required for pancreatic acinar cell autophagy. Loss of pancreatic Prkci promoted Kras-mediated pancreatic intraepithelial neoplasia formation but blocked progression to adenocarcinoma, consistent with an autophagy-dependent mechanism.\",\n      \"method\": \"Conditional pancreas-specific Prkci knockout mouse, histology, immunostaining for P62/autophagy markers, caerulein pancreatitis model, KrasG12D cancer progression model\",\n      \"journal\": \"Cancers\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — conditional KO with multiple tissue-specific readouts in vivo, epistasis with Kras\",\n      \"pmids\": [\"35159064\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"A point mutation in Prkci (identified in Tvrm323 mice) acts as a genetic modifier of Crb1-associated retinal dysplasia. Epistasis analysis showed the increased dysplastic phenotype required homozygosity of the Crb1rd8 allele, establishing Prkci as a modifier gene that shapes Crb1-associated retinal disease, likely through its role in apicobasal polarity.\",\n      \"method\": \"Chemical mutagenesis screen, genetic mapping, exome sequencing, epistasis analysis, immunohistology, electroretinography\",\n      \"journal\": \"PLoS genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in mouse model, but mechanism not fully defined at molecular level\",\n      \"pmids\": [\"35675330\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"PRKCI mediates radiosensitivity in cervical cancer through the Hedgehog/GLI1 pathway. PRKCI functions downstream of the Hh/GLI1 pathway, phosphorylating and activating transcription factor GLI1. PRKCI knockdown alters GLI1 relocalization and phosphorylation, increasing radiosensitivity, and the PKCι inhibitor auranofin acts as a radiosensitizer in vitro and in vivo.\",\n      \"method\": \"Knockdown/overexpression, colony formation assay, flow cytometry (apoptosis/cell cycle), Western blot, immunofluorescence, xenograft\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2–3 — KD with multiple readouts, pathway placement, but GLI1 phosphorylation not directly demonstrated in vitro\",\n      \"pmids\": [\"35785194\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"PRKCI interacts with SQSTM1/p62 (by co-immunoprecipitation) in osteosarcoma cells. Knockdown of PRKCI inhibits proliferation, migration, invasion, and arrests cell cycle at G2/M, operating through inactivation of the Akt/mTOR signaling pathway.\",\n      \"method\": \"Co-immunoprecipitation, siRNA knockdown, CCK-8, transwell, flow cytometry, Western blot for Akt/mTOR pathway\",\n      \"journal\": \"Frontiers in oncology\",\n      \"confidence\": \"Low\",\n      \"confidence_rationale\": \"Tier 3 — single Co-IP, single lab, KD phenotype without mechanistic reconstitution\",\n      \"pmids\": [\"39015499\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Rare loss-of-function variants in PRKCI cause Van der Woude syndrome (lower lip pits and orofacial clefts). Functional validation in zebrafish confirmed three alleles (p.Arg130His, p.Asn383Ser, p.Leu385Phe) as loss-of-function. Phosphomimetic IRF6 rescues aPKC inhibition effects, placing PRKCI upstream of IRF6 in the periderm transcriptional regulatory network governing palatal fusion.\",\n      \"method\": \"Zebrafish functional assay (enveloping layer/periderm), genetic analysis of de novo variants, phosphomimetic IRF6 rescue experiment\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple alleles functionally validated in zebrafish, epistasis with IRF6 established by rescue\",\n      \"pmids\": [\"40902599\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"The PAR6B-PRKCI-PAR3 polarity complex regulates the cell cycle of type II alveolar epithelial cells (AEC2s). Reduced PAR3-PARD6B-PRKCI complex levels arrest AEC2 cell cycle in the G0-G1 phase, impairing self-proliferation and contributing to abnormal alveolar repair in the emphysema subtype of COPD.\",\n      \"method\": \"Co-immunoprecipitation, mass spectrometry, 3D spheroid formation, viral transfection, cell cycle analysis\",\n      \"journal\": \"Stem cell research & therapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — Co-IP/MS identifies complex, functional assay links complex to cell cycle; single lab\",\n      \"pmids\": [\"40001200\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Prkci phosphorylates and stabilizes TGFβ receptor 1 (Tgfbr1), preventing its proteasomal degradation and amplifying downstream TGF-β signaling cascades in colorectal cancer. This stabilization promotes epithelial-to-mesenchymal transition, migration, and invasion. In vivo, Prkci knockout significantly reduced liver and lung metastases in mouse models.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay (phosphorylation of Tgfbr1), proteasome inhibitor rescue, EMT marker analysis, Prkci knockout mouse xenograft\",\n      \"journal\": \"Cell communication and signaling\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct substrate phosphorylation shown, stabilization mechanism validated, in vivo confirmation; single lab\",\n      \"pmids\": [\"40382656\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Prkci phosphorylates c-Myc at serine 21, inhibiting its ubiquitin-mediated proteasomal degradation and stabilizing c-Myc protein. The pro-proliferative effect of Prkci in colorectal cancer is dependent on c-Myc S21 phosphorylation. Prkci deletion in mouse models significantly delayed tumor growth and improved survival.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assay, site-directed mutagenesis (S21 phosphosite), ubiquitination assay, Prkci knockout mouse tumor model\",\n      \"journal\": \"NPJ precision oncology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — direct phosphorylation at defined site, mutagenesis confirms site, in vivo validation; single lab\",\n      \"pmids\": [\"41188443\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Prkci promotes tumor angiogenesis in colorectal cancer by phosphorylating Jak2 at serine 633, leading to downstream Stat3 activation and increased Vegfa expression. In vitro, Prkci overexpression enhanced endothelial cell proliferation, migration, and tube formation. Prkci knockout in CRC cells significantly reduced tumor growth and angiogenesis in vivo.\",\n      \"method\": \"In vitro kinase assay (Jak2 S633 phosphorylation), endothelial cell functional assays (proliferation, migration, tube formation), Prkci knockout xenograft\",\n      \"journal\": \"Neoplasia (New York, N.Y.)\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 1–2 — direct phosphorylation at defined site, multiple in vitro/in vivo functional readouts; single lab\",\n      \"pmids\": [\"40840329\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"Neural progenitor-specific ablation of both Prkci and Prkcz aPKC paralogs in mouse brain reveals a critical developmental window wherein aPKC kinase function is indispensable for neurodevelopment. A kinase-inactive PRKCI knock-in confirms that catalytic activity is required during this window. Outside this period, loss of both aPKCs causes unexpectedly mild effects.\",\n      \"method\": \"Conditional knockout mice (neural stem cells, neurons, astrocytes, NG2+ cells), kinase-inactive knock-in, gross brain morphology and viability assessment\",\n      \"journal\": \"bioRxiv\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — kinase-dead knock-in confirms catalytic requirement; preprint, single lab\",\n      \"pmids\": [],\n      \"is_preprint\": true\n    }\n  ],\n  \"current_model\": \"PKCι (PRKCI) is an atypical serine-threonine kinase that functions as a catalytic component of the evolutionarily conserved PAR3-PAR6-aPKC polarity complex (linked to Cdc42 via Par6) to establish and maintain apicobasal epithelial polarity, tight junctions, and oriented cell division; it activates NF-κB by phosphorylating IKKβ (facilitated by the p62-RIP scaffold via PB1 domain interactions); in cancer contexts it phosphorylates SOX2 to drive Hedgehog/HHAT expression, phosphorylates GLI1, Tgfbr1, Jak2 (S633), and c-Myc (S21) to promote oncogenic signaling, metastasis, and angiogenesis; and it sustains autophagy flux through the PIK3CA/AKT-MTOR pathway in pancreatic acinar cells, while loss-of-function variants cause Van der Woude syndrome by disrupting periderm differentiation upstream of IRF6.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"PRKCI (PKCι) is an atypical protein kinase C isoform that functions as a central regulator of apicobasal cell polarity, asymmetric cell division, and oncogenic signaling. As a component of the PAR6B–PRKCI–PAR3 polarity complex, its catalytic activity is required for polarized epithelial organization during cardiac morphogenesis, embryonic cavitation, neural progenitor self-renewal, and alveolar epithelial cell cycle progression [PMID:16319113, PMID:27312576, PMID:19449304, PMID:40001200]. In cancer, PRKCI phosphorylates multiple oncogenic substrates—SOX2 (driving Hedgehog/HHAT transcription in lung squamous cell carcinoma), Tgfbr1 (stabilizing TGF-β signaling to promote EMT), c-Myc at S21 (preventing ubiquitin-mediated degradation), and Jak2 at S633 (activating Stat3/VEGFA-dependent angiogenesis)—and cooperates with ECT2 and SOX2 to transform lung basal stem cells [PMID:24525231, PMID:40382656, PMID:41188443, PMID:40840329, PMID:31968252]. Loss-of-function variants in PRKCI cause Van der Woude syndrome, acting upstream of the transcription factor IRF6 in periderm development [PMID:40902599].\",\n  \"teleology\": [\n    {\n      \"year\": 2005,\n      \"claim\": \"Establishing that PRKCi is required cell-autonomously for epithelial polarity and tissue morphogenesis resolved whether this atypical PKC has a direct developmental role beyond generic kinase signaling.\",\n      \"evidence\": \"Genetic mosaic and catalytic-dead rescue in zebrafish heart development\",\n      \"pmids\": [\"16319113\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Direct phosphorylation substrates mediating polarity were not identified\",\n        \"Relationship to the PAR complex was inferred but not biochemically dissected in this system\"\n      ]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Demonstrating that PrkCi controls the division plane orientation of neural precursors linked polarity kinase function to asymmetric stem cell division and cell fate determination.\",\n      \"evidence\": \"Time-lapse imaging of spinal cord precursor divisions in zebrafish has mutants\",\n      \"pmids\": [\"19449304\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Substrates phosphorylated during neural precursor division were not identified\",\n        \"Whether this role is conserved in mammalian neural progenitors was not tested\"\n      ]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identifying SOX2 as a direct PRKCI substrate that is recruited to the HHAT promoter upon phosphorylation established the first defined kinase-transcription factor axis through which PRKCI drives an oncogenic Hedgehog signaling program in lung squamous cell carcinoma.\",\n      \"evidence\": \"Co-IP, ChIP for HHAT promoter occupancy, phosphorylation assays, in vivo loss-of-function\",\n      \"pmids\": [\"24525231\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"The specific SOX2 phosphorylation site was not mapped to single residue resolution in this study\",\n        \"Whether additional transcription factors are similarly regulated was not addressed\"\n      ]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Two parallel advances clarified PRKCI's roles in autophagy suppression and non-autonomous polarity signaling: PRKCI negatively regulates autophagy through the PIK3CA/AKT-MTOR axis, and Prkci-null cells fail to produce (but can respond to) polarity cues during cavitation.\",\n      \"evidence\": \"siRNA/overexpression with autophagic flux assays and dominant-negative mutants (L485M, P560R); Prkci−/− ES cell chimera experiments with polarity marker immunofluorescence\",\n      \"pmids\": [\"26792725\", \"27312576\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"The direct PRKCI substrate linking it to MTOR suppression was not identified\",\n        \"The molecular identity of the non-autonomous polarity signal is unknown\",\n        \"Autophagy findings relied on overexpression/knockdown without in vivo validation at that time\"\n      ]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Extending PRKCI's oncogenic repertoire, transgenic mouse models showed that PRKCI promotes immune-suppressive TNFα signaling and activates YAP1 in ovarian cancer, broadening the downstream effector landscape beyond Hedgehog.\",\n      \"evidence\": \"Transgenic mouse ovarian cancer models with pathway analysis and loss-of-function\",\n      \"pmids\": [\"28698296\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether PRKCI directly phosphorylates YAP1 or acts indirectly was not resolved\",\n        \"TNFα upregulation mechanism (transcriptional vs. post-translational) was not defined\"\n      ]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Demonstrating that PRKCI, SOX2, and ECT2 together transform Trp53-null mouse lung basal stem cells defined a minimal oncogenic cooperation module and separated PRKCI's lineage-specifying (via SOX2) from growth-promoting (via ECT2) functions.\",\n      \"evidence\": \"Mouse transformation assay with defined genetic combinations, gene expression profiling, in vivo tumor modeling\",\n      \"pmids\": [\"31968252\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"Whether ECT2 is a direct PRKCI substrate was not established\",\n        \"Applicability to non-squamous lung cancer subtypes is untested\"\n      ]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Pancreas-specific Prkci ablation confirmed the autophagy-regulating role in vivo: loss causes P62 aggregation, autophagic vesicle depletion, and acinar cell damage, and unexpectedly blocks Kras-driven progression from PanIN to adenocarcinoma.\",\n      \"evidence\": \"Conditional knockout mice with Kras-driven pancreatic tumorigenesis, immunohistochemistry, autophagic vesicle quantification\",\n      \"pmids\": [\"35159064\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\n        \"How PRKCI sustains autophagic flux at the molecular level (direct substrates in acinar cells) remains uncharacterized\",\n        \"The paradox of promoting early neoplasia but being required for adenocarcinoma progression is mechanistically unexplained\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Multiple substrate-level discoveries in colorectal cancer identified Tgfbr1, c-Myc (S21), and Jak2 (S633) as direct PRKCI phosphorylation targets that stabilize oncoproteins or activate pro-angiogenic signaling, greatly expanding the known substrate repertoire.\",\n      \"evidence\": \"Co-IP, site-specific mutagenesis, ubiquitination assays, phosphorylation site identification, in vivo Prkci knockout xenograft and metastasis models\",\n      \"pmids\": [\"40382656\", \"41188443\", \"40840329\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Each substrate was identified by a single lab; independent replication is pending\",\n        \"Whether these substrates are phosphorylated in non-CRC contexts is unknown\",\n        \"Structural basis for PRKCI recognition of these diverse substrates is undefined\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identification of PRKCI loss-of-function variants as causal for Van der Woude syndrome, with epistasis placing PRKCI upstream of IRF6, established the first Mendelian disease linked to this gene.\",\n      \"evidence\": \"Patient variant functional testing in zebrafish enveloping layer assay, phosphomimetic IRF6 rescue\",\n      \"pmids\": [\"40902599\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"Whether PRKCI directly phosphorylates IRF6 or acts through an intermediate is not resolved\",\n        \"The specific periderm cell biological defect downstream of PRKCI loss in human palate is not characterized\"\n      ]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"The PAR6B–PRKCI–PAR3 complex was shown to regulate alveolar epithelial type II cell self-renewal by controlling cell cycle progression, linking the polarity complex to adult lung stem cell maintenance.\",\n      \"evidence\": \"Co-IP, mass spectrometry, 3D spheroid assays from primary mouse AEC2s, cell cycle analysis\",\n      \"pmids\": [\"40001200\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\n        \"The PRKCI substrate mediating G0/G1 arrest upon complex reduction is unknown\",\n        \"Whether this mechanism operates in human emphysema AEC2s requires validation\"\n      ]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"A unified structural and signaling model integrating PRKCI's polarity and oncogenic functions—explaining how the same kinase drives epithelial organization in normal tissues yet phosphorylates diverse oncogenic substrates in cancer—remains unestablished.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\n        \"No structural model of PRKCI in complex with PAR6/PAR3 or with oncogenic substrates exists\",\n        \"Systematic substrate identification across normal and cancer contexts has not been performed in mammalian systems\",\n        \"The switch between polarity-maintaining and oncogenic modes is not mechanistically defined\"\n      ]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 12, 13, 14]},\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [5, 11]},\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [2, 10, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [0, 1, 5, 11, 12, 14]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [2, 8, 10, 15]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [5, 6]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [18]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [7, 13, 14]}\n    ],\n    \"complexes\": [\n      \"PAR6B-PRKCI-PAR3 polarity complex\"\n    ],\n    \"partners\": [\n      \"SOX2\",\n      \"ECT2\",\n      \"PAR6B\",\n      \"PAR3\",\n      \"RIPK2\",\n      \"SQSTM1\",\n      \"TGFBR1\",\n      \"JAK2\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"PRKCI encodes protein kinase C iota, an atypical serine/threonine kinase that functions as the catalytic component of the evolutionarily conserved PAR3–PAR6–aPKC polarity complex, where it is essential for establishing apicobasal epithelial polarity, tight junction biogenesis, oriented cell division, and tissue morphogenesis in contexts ranging from cardiac development to neural progenitor self-renewal [PMID:10934474, PMID:11257119, PMID:16319113, PMID:19449304]. Through its PB1 domain, PKCι scaffolds with p62/SQSTM1 and RIP to activate NF-κB by directly phosphorylating IKKβ at Ser177/Ser181, and it sustains autophagy flux via the PIK3CA/AKT–mTOR axis in pancreatic acinar cells [PMID:10022904, PMID:10356400, PMID:35159064]. In oncogenic settings, PKCι phosphorylates SOX2 to drive Hedgehog ligand production, stabilizes c-Myc (Ser21) and TGFβR1 against proteasomal degradation, and phosphorylates Jak2 (Ser633) to promote STAT3-dependent angiogenesis [PMID:24525231, PMID:41188443, PMID:40382656, PMID:40840329]. Rare loss-of-function PRKCI variants cause Van der Woude syndrome by disrupting periderm differentiation upstream of IRF6 [PMID:40902599].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"Molecular cloning of PRKCI established it as a novel atypical PKC isoform most closely related to PKCζ, possessing serine/threonine kinase activity but lacking the Ca²⁺-binding and dual cysteine-rich motifs of conventional PKCs, thereby defining a distinct regulatory input logic for this branch of the PKC family.\",\n      \"evidence\": \"cDNA cloning, Northern/Western blot, in vitro kinase assay in CHO-K1 cells\",\n      \"pmids\": [\"8226978\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No endogenous substrates identified\", \"Tissue-specific expression pattern not fully mapped\", \"Activation mechanism in cells unknown\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Identification of Par-4 as a specific inhibitor of atypical PKCs (including PKCι) that promotes apoptosis established that PKCι kinase activity functions as a pro-survival signal, answering whether atypical PKCs have roles beyond conventional PKC-regulated pathways.\",\n      \"evidence\": \"Co-immunoprecipitation, in vitro kinase assay, kinase-dead mutant rescue in NIH-3T3 cells\",\n      \"pmids\": [\"8797824\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism by which Par-4 inhibits aPKC catalytic activity not resolved\", \"Downstream survival substrates not identified\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Demonstration that PKCι directly phosphorylates IKKβ (Ser177/Ser181) and that the scaffold protein p62 bridges PKCι to RIP in the TNFα pathway placed PKCι at a defined position in NF-κB activation, resolving how atypical PKCs connect receptor signaling to IKK.\",\n      \"evidence\": \"In vitro kinase assay, site-directed mutagenesis, dominant-negative transfection, antisense p62, NF-κB reporter\",\n      \"pmids\": [\"10022904\", \"10356400\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of PKCι vs. PKCζ to NF-κB in vivo not resolved\", \"Structural basis of p62–aPKC interaction unknown at this time\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Discovery that PKCι forms a ternary complex with Par6, Par3, and Cdc42-GTP at tight junctions revealed the conserved polarity machinery through which PKCι controls epithelial apicobasal polarity, answering how a kinase connects Rho-family GTPase signaling to junction formation.\",\n      \"evidence\": \"Yeast two-hybrid, reciprocal Co-IP, dominant-negative expression, tight junction permeability assay in epithelial cells\",\n      \"pmids\": [\"10934474\", \"11257119\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct phosphorylation substrates within the polarity complex not identified\", \"How kinase activity remodels the complex unclear\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Mapping the PB1 domain as the module mediating PKCι interactions with both p62 and Par6 unified the NF-κB and polarity functions under a single structural interface, explaining how one kinase is routed to distinct pathways through competitive PB1-mediated scaffolding.\",\n      \"evidence\": \"Mutagenesis of basic/acidic charge residues, Co-IP, yeast two-hybrid\",\n      \"pmids\": [\"12813044\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether p62 and Par6 binding is mutually exclusive in vivo not tested\", \"No crystal structure of the PB1 heterodimer at this time\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Genetic studies in zebrafish demonstrated that PKCι catalytic activity is required tissue-autonomously for cardiac and neural progenitor polarity and morphogenesis, extending the polarity function from cultured epithelial cells to in vivo organogenesis.\",\n      \"evidence\": \"Zebrafish heart-and-soul mutant rescue with catalytic-dead mutant, mosaic analysis, live imaging; spinal cord progenitor division analysis\",\n      \"pmids\": [\"16319113\", \"19449304\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"In vivo substrates mediating cardiac morphogenesis unknown\", \"Whether PKCζ compensates partially in zebrafish not addressed\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of SOX2 as a direct PKCι substrate whose phosphorylation drives HHAT transcription and Hedgehog ligand production revealed the first oncogenic phosphorylation circuit for PKCι, explaining how 3q26 amplification promotes lung squamous cell carcinoma stemness.\",\n      \"evidence\": \"In vitro kinase assay, ChIP, siRNA, reporter assay, mouse tumor model\",\n      \"pmids\": [\"24525231\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"SOX2 phosphosite(s) not fully mapped\", \"Whether this axis operates in non-lung cancers unclear\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"PRKCI was shown to suppress autophagy via PIK3CA/AKT–mTOR activation, while dominant-negative PRKCI mutants induced autophagy, establishing a kinase activity–dependent regulation of autophagic flux that complemented the polarity and NF-κB branches of PKCι signaling.\",\n      \"evidence\": \"siRNA knockdown, overexpression, dominant-negative mutants (L485M, P560R), LC3B-II flux assay in U2OS cells\",\n      \"pmids\": [\"26792725\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct mTOR pathway substrate of PKCι not identified\", \"Cell-type generalizability not tested beyond U2OS\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Coordinate amplification of PRKCI, SOX2, and ECT2 on 3q26 was shown to be sufficient—with Trp53 loss—to transform mouse lung basal stem cells into LSCC, and PKCι interaction with RIPK2 was found to enhance NF-κB/JNK/ERK signaling in pancreatic cancer, expanding the oncogenic substrate repertoire of PKCι.\",\n      \"evidence\": \"Mouse basal stem cell transformation, gene expression profiling; Co-IP of PRKCI–RIPK2, xenograft\",\n      \"pmids\": [\"31968252\", \"37016317\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"ECT2 mechanism downstream of PKCι not molecularly defined\", \"RIPK2 phosphosite not mapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Conditional pancreatic Prkci knockout demonstrated that PKCι is required for autophagy in acinar cells in vivo and that its loss promotes early neoplasia but blocks adenocarcinoma progression, resolving a context-dependent tumor-suppressive versus oncogenic duality for PKCι.\",\n      \"evidence\": \"Pancreas-specific Prkci KO mouse, KrasG12D epistasis, P62 aggregation/autophagy marker analysis, caerulein pancreatitis\",\n      \"pmids\": [\"35159064\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct autophagy substrate of PKCι in acinar cells not identified\", \"Whether autophagy loss is the sole mechanism blocking PDAC progression unclear\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"A series of studies identified three new direct PKCι substrates—TGFβR1 (stabilized against proteasomal degradation), c-Myc (Ser21 phosphorylation prevents ubiquitination), and Jak2 (Ser633 phosphorylation activates STAT3/VEGFA)—collectively explaining PKCι's roles in EMT, proliferation, and angiogenesis in colorectal cancer.\",\n      \"evidence\": \"In vitro kinase assays with site-directed mutagenesis, ubiquitination assays, endothelial tube formation, Prkci KO xenograft models\",\n      \"pmids\": [\"40382656\", \"41188443\", \"40840329\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"All three substrates reported by a single group; independent replication needed\", \"Structural basis of substrate recognition not determined\", \"Relative contribution of each substrate to in vivo tumor phenotype not dissected\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Rare loss-of-function PRKCI variants were identified as a cause of Van der Woude syndrome, with epistasis experiments placing PKCι upstream of IRF6 in the periderm differentiation program required for palatal fusion—the first Mendelian disease linked to PRKCI.\",\n      \"evidence\": \"Human genetic analysis of de novo variants, zebrafish functional validation of three alleles, phosphomimetic IRF6 rescue\",\n      \"pmids\": [\"40902599\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct phosphorylation of IRF6 by PKCι not demonstrated\", \"Genotype-phenotype spectrum across additional VWS families not established\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the full repertoire of direct PKCι substrates in polarity and autophagy contexts, the structural basis for PKCι substrate selectivity versus PKCζ, and whether the recently identified oncogenic substrates (TGFβR1, c-Myc, Jak2) are relevant across cancer types beyond colorectal cancer.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No crystal structure of full-length PKCι in complex with a substrate\", \"Isoform-specific (ι vs. ζ) substrate selectivity mechanism unknown\", \"Therapeutic window for PKCι inhibition in cancer vs. normal polarity not defined\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [0, 2, 10, 23, 24, 25]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [0, 2, 10, 23, 24, 25]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005886\", \"supporting_discovery_ids\": [4, 5]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [11, 20]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [2, 3, 13, 16, 25]},\n      {\"term_id\": \"R-HSA-1500931\", \"supporting_discovery_ids\": [4, 5, 22]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [2, 3, 13]},\n      {\"term_id\": \"R-HSA-9612973\", \"supporting_discovery_ids\": [11, 17]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [7, 8, 21]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [10, 15, 19, 23, 24, 25]}\n    ],\n    \"complexes\": [\n      \"PAR3–PAR6–aPKC polarity complex\",\n      \"p62–RIP–aPKC NF-κB signaling complex\"\n    ],\n    \"partners\": [\n      \"PARD6B\",\n      \"PARD3\",\n      \"CDC42\",\n      \"SQSTM1\",\n      \"RIPK1\",\n      \"SOX2\",\n      \"RIPK2\",\n      \"IKBKB\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}